EP0248594A2 - Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same - Google Patents

Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same Download PDF

Info

Publication number
EP0248594A2
EP0248594A2 EP87304720A EP87304720A EP0248594A2 EP 0248594 A2 EP0248594 A2 EP 0248594A2 EP 87304720 A EP87304720 A EP 87304720A EP 87304720 A EP87304720 A EP 87304720A EP 0248594 A2 EP0248594 A2 EP 0248594A2
Authority
EP
European Patent Office
Prior art keywords
methoxyphenyl
chlorophenyl
pyrazolyl
lower alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87304720A
Other languages
German (de)
French (fr)
Other versions
EP0248594B1 (en
EP0248594A3 (en
Inventor
Michael Paul Wachter
Michael Paul Ferro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to AT87304720T priority Critical patent/ATE97660T1/en
Publication of EP0248594A2 publication Critical patent/EP0248594A2/en
Publication of EP0248594A3 publication Critical patent/EP0248594A3/en
Application granted granted Critical
Publication of EP0248594B1 publication Critical patent/EP0248594B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/84Unsaturated compounds containing keto groups containing six membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/88Unsaturated compounds containing keto groups containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to substituted pyrazole derivatives, and particularly to 1,5-diaryl 3-substituted-pyrazoles that are pharmacologically active in alleviating inflammation, asthma, hypersensitivity, myocardial ischemia, dermatological conditions such as psoriasis, dermatitis and gastrointestinal inflammatory conditions such as inflammatory bowel syndromes, and to a method for synthesizing those pyrazole derivatives.
  • Nonsteroidal anti-inflammatory drugs such as indomethacin, naproxen, ibuprofen, tolectin, fenoprofen and the like have generally been shown to attenuate the biosynthesis of prostaglandins by inhibiting the activity of the enzyme cyclooxygenase.
  • the prostaglandin end-products of the cyclooxygenase pathway are responsible for many of the early signs of inflammation including hyperalgesia, increases in vascular permeability leading to edema, and pyrexia.
  • the activity and potency of the NSAID's in reducing these signs and symptoms is, for the most part, correlated with their ability to inhibit prostaglandin biosynthesis.
  • the other major pathway of arachidonic acid metabolism is the lipoxygenase pathway.
  • Lipoxygenase products of arachidonate metabolism, the leukotrienes, hydroxyeicosatetraenoic acids (HETES) and hydroperoxyeicosatetraenoic acids (HEPTES) have been shown or implicated to be involved in disease states including acute and chronic inflammation, arthritis, allergic and other hypersensitivity disorders, dermatological diseases such as psoriasis, acne, atopic dermatitis, contact sensitivity, eczema and others, cardiovascular disorders secondary to myocardial ischemia or infarction, thromboembolism or vasculitis or platelet aggregation, and hyperalgesic disorders, gynecological disorders such as dysmenorrhea, ocular inflammation, sperm motility or function, and others.
  • Leukotriene B4 (LTB4), another product of the lipoxygenase pathway, as well as HETES and HPETES can mediate induction of other phlogistic substances such as thromboxanes and prostacyclin, is chemotactic to inflammatory cells and is hyperalgesic. Many of these mediators have been identified in skin, lungs, coronary circulation, eyes, gastrointestinal tract and other organs, and in the synovial fluid of rheumatoid arthritic patients. In chronic inflammatory conditions such as rheumatoid arthritis, it is believed to be the chronic influx of leukocytes, probably mediated by LTB4, that is the eventual cause of joint erosion.
  • Pharmacologically active compounds that can inhibit both enzyme pathways at similar concentrations (dual inhibitors) provide a more complete relief for patients suffering from arthritis, hypersensitivity, dermatological, cardiovascular, gastrointestinal, ocular, and gynecological disorders than present drugs that inhibit one pathway, but not the other as is the case for usually used NSAID's that are predominantly inhibitors of the cyclooxygenase (prostaglandin synthesis) pathway.
  • Vereshchagin et al., Zh. Org. Khim., 7 :907-912 (1971) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles.
  • the 3-substituents were reported to be alkoxy alkylene in which the alkoxy radical was methoxy or phenoxy and the alkylene was methylene or isopropylene, while the 1,5-diaryl radicals were unsubstituted phenyl.
  • the present invention contemplates 1,5-diaryl-3-substituted pyrazoles, their use and a method of their synthesis.
  • the compounds of the present invention are pharamacologically active in alleviating inflammation, and inhibit the cyclooxygenase enzyme pathway, the lipoxygenase enzyme pathway, or preferably both pathways.
  • the invention contemplates a substituted pyrazole compound having a structure that conforms to the formula wherein R1, R2, R3 and R4 are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, amino, acetamido, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, ⁇ -trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R1, R2 or R3, R4 taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group; R is a straight, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms; Y is hydrogen, bromo, chloro or lower alkyl having 1-4 carbon atoms; and X is selected from the group consisting of carboxy, carbolow
  • R2 and R4 are hydrogen, and R1 and R3 are selected from the group consisting of halo, trifluroromethyl, lower alkyl and lower alkoxy, especially methoxy.
  • R preferably contains two carbon atoms.
  • the X be hydroxyloweralkyl, carboxy, a hydroxamic acid or a N alkyl hydroxamic acid; i.e., that X be C(O)NR6R7 where R6 is hydroxy and R7 is hydrogen or lower alkyl or a N-alkyl hydroxamic acid; i.e. that x is -C(O)NR6R7 wheren R6 is hydroxy or -OC(O)CH2Z where Z is dialkylamino or -CH2CO2H and R7 is hydrogen or lower alkyl.
  • the present invention also contemplates a pharmaceutical composition that comprises an anti-inflammatory amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier.
  • the dose may be administered by topical, p.o., parenteral or aerosol routes.
  • that substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and the lipoxygenase pathways in the amount present in the composition, when the composition is introduced into a mammal.
  • That method comprises administering to that mammal a pharmaceutical composition that includes as the active ingredient an effective amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier for topical, oral, parenteral and aerosol administration.
  • a method for synthesizing a 1,5-diaryl-3-(omega-substituted lower alkyl)pyrazole is also contemplated.
  • an aryl hydrazine or its acid addition salt is reacted with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain.
  • a polar solvent is used that is substantially inert to the reaction conditions, as is the omega-substituent of the alkyl 1,3-dione.
  • the resulting 1,5-diaryl-3-(omega lower alkyl substituted) pyrazole is thereafter preferably recovered, although it can be utilized in the form of its synthesis (crude form), as for further syntheses.
  • Particularly preferred alkyl-1,3-dione derivatives contain 6 carbons in the alkyl chain and contain a hydroxy group as the omega-substituent.
  • the present invention provides several benefits and advantages.
  • a particular benefit of the invention is that it provides pharmacologically active compounds that are useful in treating inflammatory conditions.
  • a particular advantage of the present invention is that its synthetic method provides relatively high yields of 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole compounds.
  • Another benefit of the present invention is that some of its pharmacologically active compounds inhibit the cyclooxygenase enzyme pathway, thereby providing a further means for studying that biological process.
  • Another advantage of the present invention is that some of its pharmacologically active compounds inhibit the lipoxygenase enzyme pathway, thereby providing a further means for studying that biological process.
  • 1,5-Diaryl-3-substituted pyrazole compounds pharmaceutical compositions containing a substituted pyrazole compound as an active ingredient, a method of treating a mammal exhibiting an inflammatory condition and a method of synthesizing the substituted pyrazole compound are contemplated herein.
  • R1, R2, R3 and R4 are substituents on phenyl rings that substitute for hydrogen atoms at positions 1 and 5 of the pyrazole ring. It is preferred that at least one of R1 and R2, and one of R3 and R4 be substituted at the 4-positions of their respective phenyl rings.
  • R1, R2, R3 and R4 radicals and the X group can be a "lower” alkyl, “lower” alkoxy and the like.
  • Groups and radicals referred to as “lower” denote that they possess 1 to about 6 carbon atoms. The same is true for “lower” groups and radicals that are sustituents of the "lower” groups and radicals enumerated.
  • Lower alkyl radicals include, for example, methyl, ethyl, propyl, isopropyl, n -butyl, sec -butyl, t -butyl, n -pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n -hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, octyl and the like.
  • Lower alkoxy radicals are oxygen ethers formed from a before-described lower alkyl group.
  • Exemplary radicals include methoxy, ethoxy, propoxy, isopropoxy, n -butoxy, and the like.
  • Lower alkylthio radicals of R1,R2,R3 and R4 are sulfide ethers and are thus analogous to the oxygen ethers described above.
  • Halo radicals preferably include chloro and bromo, as well as fluoro and iodo.
  • Lower alkylsulfonyl radicals contain a before-described lower alkyl radical bonded to an SO2 moiety that is itself also bonded to a phenyl ring.
  • Exemplary lower alkylsulfonyl radicals thus include methylsulfonyl, ethylsulfonyl, 2-ethylbutylsulfonyl and the like.
  • An omega-trifluoromethyl lower alkoxy radical is a lower alkoxy radical as before described that additionally includes a trifluoromethyl group at a position farthest on the alkyl chain from the place of bonding to the phenyl ring.
  • Exemplary of such radicals are the 2,2,2-trifluoroethoxy.
  • Naphthyl and substituted naphthyl radicals can replace an aryl group herein at either the 1- or 2-positions to provide 1-naphthyl or 2-napththyl substituents, respectfully.
  • Substituents on the naphthyl radicals can be any of those described herein as being useful aryl substituents.
  • Exemplary substituted 1- and 2-naphthyls include 6-methoxy-2-naphthyl and the like.
  • Lower alkyl carboxy radicals are the before-described lower alkyl radicals that further include a carboxy group.
  • Exemplary lower alkyl carboxy radicals include carboxymethyl, 2-carboxyhexyl and the like.
  • Lower alkyl lower alkoxy carbonyl radicals are lower alkyl esters of lower alkyl carboxy radicals.
  • Exemplary lower alkyl lower alkoxy carbonyl radicals include 3-iso­propoxycarbonylpropyl, 4-hexyloxycarbonylpentyl and the like.
  • a lower alkyl carbonyl radical contains a carbonyl group, a total of up to six carbon atoms, and with the portion of R to which it is linked, forms a ketone at the R/X junction.
  • Exemplary lower alkyl carbonyl radicals include acetyl, propionyl 2-methylpropionyl, pentoyl and the like, which can also be named methyl carbonyl, ethyl carbonyl, isopropylcarbonyl and butylcarbonyl, respectively.
  • Radicals in which X is C(O)-R5 where in R5 is lower alkoxy are carboxylic esters. These esters are preferably named by considering R-X to be a single substituent entity. Exemplary R5 lower alkoxy groups are as before described, although methoxy and ethoxy are preferred. When R5 is NR6R7 and ONR8R9, it is also useful to consider R-X as a substituent entity.
  • Lower hydroxy alkyl radicals of R6 and R7 are preferably 2-hydroxyethyl and 2-hydroxypropyl. Additionally useful lower hydroxy alkyl radicals include 4-hydroxybutyl and the like.
  • Substituted phenyl radicals that can comprise NR6R7 are the same as the substituted aryl groups described before wherein R1, R2, R3 and R4 comprise the substituents.
  • Pyridyl radicals are derivatives of pyridine and can be bonded to the nitrogen atom of NR6R7 at the 2-, 3- or 4-positions relative to the pyridine nitrogen.
  • R in the structural formula above is a straight, saturated or unsaturated hydrocarbyl radical that contains 2 to about 16 carbon atoms.
  • the R-X radical together contains three saturated carbon atoms linked together by carbon-carbon bonds.
  • R is unsaturated and contains 7-16 carbon atoms.
  • R is a hydrocarbon radical and therefore contains no elements other than carbon and hydrogen. Consequently, any element present in R-X that is not hydrogen or carbon is, by definition, part of the X radical.
  • compositions are useful herein, and can be formed by treatment of the pyrazole with an appropriate acid.
  • exemplary inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric and the like acids.
  • exemplary organic acids include methanesulfonic, ethanesulfonic, benzenesulfonic and p -toluenesulfonic and the like acids.
  • the acid addition salt form can be converted to the free base form by treatment with alkali.
  • 1,5-Diaryl-3-substituted pyrazole compounds can include a carboxylic acid and/or a hydroxamic acid, as already noted.
  • Basic salts of those carboxylic and hydroxamic acids are also contemplated, and are formed by treatment of the acid with an appropriate, non-toxic, pharmaceutically acceptable alkaline reagent to form a carboxylate or hydroxamate cation salt.
  • Exemplary non-toxic, pharmaceutically acceptable cation salts of such carboxylic and hydroxamic acids include sodium, potassium, zinc, aluminum, calcium and magnesium. These salts also readily form in aqueous solutions of the carboxylic and hydroxamic acids.
  • R2 and R4 are hydrogen, and R1 and R3 are selected from the group consisting of halo and lower alkoxy, especially methoxy.
  • the preferred R1 and R3 substituents are preferably at the 4-positions of their respective aryl (phenyl) rings.
  • R contain two carbon atoms and that X be carboxy, hydroxymethyl, a hydroxamic acid (N-hydroxy amide) or a N-lower alkyl hydroxamic acid (N-hydroxy-N-lower alkyl amide).
  • 1,5-diaryl-3-substituted pyrazole compounds are named hereinbelow, followed by a parenthesized, underlined numeral for ease of identification and correlation with the syntheses and anti-inflammation study described in detail hereinafter.
  • the preferred species of this invention include:
  • a pharmaceutical composition that comprises an anti-inflammatory amount of a before-discussed 1,5-diaryl-3-substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier is also contemplated herein.
  • the composition comprises a unit dosage of the substituted pyrazole compound.
  • the substituted pyrazole compounds of this invention are capable of inhibiting the lipoxygenase enzyme pathway and/or the cyclooxygenase (prostaglandin synthetase) enzyme pathway.
  • the substituted pyrazole compound of the pharmaceutical composition is capable of inhibiting both the lipoxyenase and the cyclooxygenase enzyme pathways in the amount at which that substituted pyrazole compound is present in the pharmaceutical composition, when that composition is introduced as a unit dose into an appropriate mammal such as a laboratory rat.
  • unit dosage and its grammatical equivalent is used herein to refer to physically discrete units suitable as unitary dosages for human patients and other warm blooded animals, each unit containing a predetermined effective, pharmacologic amount of the active ingredient calculated to produce the desired pharmacological effect in association with the required physiologically tolerable carrier, e.g., a diluent or a vehicle.
  • physiologically tolerable carrier e.g., a diluent or a vehicle.
  • suitable unit dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, and the like, segregated multiples of any of the foregoing, as well as liquid solutions and suspensions.
  • the active ingredient is referred to herein as being dispersed in the carrier.
  • the dispersion formed can be a simple admixture, a non-settling dispersion as in the case of certain emulsions, or as an ultimate dispersion, a true solution.
  • the amount of active ingredient that is administered in vivo depends on the age and weight of the mammal treated, the particular medical condition to be treated, the frequency of administration, and the route of administration.
  • the dose range can be about 0.01 to about 500 milligrams per kilogram of body weight, more preferably about 0.1 to about 50 milligrams per kilogram of body weight and most preferably about 0.1 to about 25 milligrams per kilogram of body weight.
  • the human adult dose is in the range of about 10 to about 2000 milligrams daily, given as a single dose or in 3 or 4 divided doses.
  • Veterinary dosages correspond to human dosages with the amounts administered being in proportion to the weight of the animal as compared to adult humans.
  • orally administered unit doses containing about 1 to about 50 milligrams of a 1,5-diaryl-3-substituted pyrazole per kilogram of laboratory rat body weight were useful in reducing inflammation.
  • Physiologically tolerable carriers are well known in the art.
  • Exemplary of liquid carriers are aqueous solutions that contain no materials in addition to the substituted pyrazole compound, or contain a buffer such as sodium phosphate at physiological pH value, saline and the like.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water.
  • additional liquid phases are glycerin and vegetable oils such as cottonseed oil.
  • Exemplary solid carriers include those materials usually used in the manufacture of pills or tablets, and include corn starch, lactose, dicalcium phosphate, thickeners such as tragacanth and methylcellulose U.S.P., finely divided SiO2, polyvinylpyrrolidone, magnesium stearate and the like.
  • Antioxidants such as methylparaben and propylparaben can be present in both solid and liquid compositions, as can sweeteners such a cane or beet sugar, sodium saccharin, sodium cyclamate and the dipeptide methyl ester sweeteneer sold under the trademark NUTRASWEET (aspartame) by G. D. Searle Co.
  • a method for alleviating inflammation in a mammal exhibiting an inflammatory condition comprises administering to that mammal an effective amount of a pharmaceutical composition that includes a unit dose of an active ingredient that is the before-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is preferably maintained within the mammal until the substituted pyrazole compound is cleared from the mammal's body by natural means such as excretion or metabolism.
  • the pharmaceutical composition can be administered orally, topically or by injection, by means well known in the art.
  • the composition is administered orally as a tablet, capsule or aqueous dispersion.
  • the method of alleviating inflammation can include administering the pharmaceutical composition a plurality of times into the treated mammal over a time period of weeks, months and years.
  • the pharmaceutical composition is administered a plurality of times to the mammal over a time period of thirty days, in preferred practice.
  • a method for synthesizing a 1,5-diaryl-(omega-substituted lower alkyl) pyrazole constitutes yet another aspect of the present invention.
  • an aryl hydrazine or its acid addition salt is admixed in an inert polar solvent with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons, and up to about 9 carbon atoms, in the alkyl chain to form a reaction mixture.
  • the aryl hydrazine and the 1,3-alkyldione are preferably reacted in substantially stoichiometric amounts.
  • the omega-substituent of the 1-aryl-omega-­substituted-alkyl-1,3-dione is substantially inert to the reaction conditions utilized for the cyclization reaction; i.e., the substituent does not itself react with any of the reactants or solvent during the cyclization reaction.
  • exemplary of useful substituents are hydroxy and lower alkoxy as before described. Hydroxy is particulary preferred as the omega substituent.
  • aryl hydrazine and aryl-alkyl-1,3-dione are reacted in an inert polar solvent medium.
  • solvents are methanol, ethanol, isopropanol, pyridine, triethylamine and mixtures of those solvents.
  • the reaction mixture so formed is maintained with agitation, as by stirring, for a predetermined period of time for the 1-aryl-hydrazine and the 1-aryl-(omega-substituted)-alkyl-1,3-dione to react and form the desired 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole.
  • the predetermined time period is typically about 1 to about 20 hours, depending upon the reactants, solvent and reaction temperature.
  • the cyclization reaction is normally carried out at ambient room temperature.
  • the temperature typically rises somewhat during the cyclization, but is readily controlled. Temperatures above room temperature can also be utilized.
  • the resulting substituted pyrazole can be used as is in its crude form directly after the cyclization, as where a further reaction is to be carried out with it.
  • the crude reaction product formed is recovered and purified as by crystallization or column chromatography prior to use in a further reaction or to alleviate inflammation.
  • reaction sequence shown thereafter in Scheme 2 relates to reactions carried out with specific compounds and in which R* is the 1-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl]methylene group (as shown hereinafter); R1-R7 are as before described; lower case letters adjacent to reaction arrows indicate reaction conditions discussed thereafter below; and underlined numerals indicate specific compounds whose syntheses are described in detail hereinafter.
  • a pyridinium chlorochromate
  • b Jones Reagent
  • c lithium hexamethyldisilazide/BrPh3P(CH2)4 CO2H
  • d oxalyl chloride
  • e R6NHOH
  • f R6R7NH.
  • the pyrazoles of formula I are oxidized to either the acid (e.g., 12 ) with, for example, Jones Reagent or to the aldehyde (e.g., 11 ) with, for example, pyridinium chlorochromate, as illustrated with compound 2 ; i.e., 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-­(4-methoxyphenyl)pyrazole.
  • the olefinic acid 32 was obtained by treatment of aldehyde 11 with (4-carboxylbutyl)triphenylphosphorane.
  • the appropriate acid chlorides were synthesized by treatment of acids of general formula 12 or 32 with oxalyl chloride in tetrahydrofuran (THF). The acid chlorides were then added as THF solutions to a solution of the appropriate alkylhydroxylamine hydrochloride [R6NHOH(HCl)] in THF/water/triethylamine (THF/H2O/Et3N) to afford the alkylhydroxamic acids such as compounds 3 , 58 and 41 .
  • the corresponding O-acylated products e.g., 53 and 57
  • that may also form in the reaction were separated by either recrystallization or chromatography.
  • Example 1 5-(4-Chlorophenyl)-3-(3-hydroxypropyl)-­1-(4-methoxyphenyl) pyrazole (2) .
  • the reaction mixture was worked up as follows: the mixture was concentrated in vacuo and taken up in diethyl ether (250 ml); the ether solution was washed with aqueous 1N HCl (200 ml), decolorized, dried (Na2SO4), filtered through a pad of celite, and concentrated in vacuo .
  • the crude material was either purified by column chromatography (silica gel 60, 70 - 230 mesh, about 250 g, and elution with ether) to give the desired 1,5-diarylpyrazoles ( I ) or recrystallized directly without chromatography. In some cases the isomeric 1,3-diaryl isomer was also isolated in varying minor amounts, and eluted before I from the column.
  • R1, R2, R3 and R4 are all other than hydrogen
  • aryl hydrazine B is 3,4-dimethoxyphenylhydrazine
  • 1-aryl-1,3-dione A is 3,4-dichloro-4,6-dioxohexanoic acid
  • 5-(3,4-dichlorophenyl)-­1-(3,4-dimethoxyphenyl)-3-(3-hydroxypropyl)-pyrazole is obtained.
  • Example 2 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propionic acid (12 ).
  • Example 3 Sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazoyl] propanoate monohydrate (13).
  • the compounds of Table 2 ⁇ -AP were synthesized by the following general procedure. To a reaction vessel containing anhydrous THF (250 ml) and diisopropylamine (14 ml, 0.1 Mole) stirring under nitrogen at 0°C was added by syringe, n-BuLi (1.6 M, 62.5 ml,0.1 Mole). The vessel was then cooled to -78°C. Alternatively, lithium hexamethyldisilazide (0.1 Mole) may be employed as the base in place of lithium diisopropylamide.
  • Example 7 0-[2-[5-(4-Chlorophenyl)-1(4-­methoxyphenyl)-3-pyrazolyl] ethyl-carbonyl]-­N-methylhydroxylamine (53).
  • Example 8 N-Carboxymethyl-3-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl]­propanamide (66).
  • Example 10 3-[5-(4-Fluorophenyl)-1-(4-methoxyphenyl)- 3-pyrazolyl]-N-hydroxy-N-methyl propanamide (45).
  • Example 12 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxypropanamide (29).
  • Example 13 0-[2-[5-(4-Chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl] ethylcarbonyl]-N- tert -butylhydroxylamine ( 57 ); and 3-[5-(4-chlorphenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-­N-tert-butyl-N-hydroxypropanamide (58).
  • reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H2O, dried (MgSO4), filtered and concentrated in vacuo . The residue was combined with that from a similar run on a 2.72 mM scale.
  • Example 15 Sodium 8-[5-(4-Chlorophenyl)-1-(4-­methoxyphenyl)-3-pyrazolyl]-5(Z)-­octenoate (32).
  • Example 16 8-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxy-N-methyl-­5(Z)-octenamide (41).
  • Example 17 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N,N-diethylpropanamide (28).
  • Example 18 Compounds of Table 3 .
  • Example 19 Compounds of Table 4 .
  • Example 20 3-(3-Acetoxypropyl)-5-(4-chlorophenyl)-­1-phenylpyrazole (7).
  • Example 21 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propyl methyl ether (24).
  • Example 22 5-(4-Chlorophenyl)-3-(3-hydroxybutyl)-­1-(4-methoxyphenyl) pyrazole (20).
  • Example 23 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-(3-oxobutyl)pyrazole (23).
  • Example 24 5-(4-Chlorophenyl)-3-(3-hydroxy-3-methylbutyl)-­1-(4-methoxyphenyl) pyrazole (27).
  • Example 25 5-(4-Chlorophenyl)-3-(3-oximinopropyl)-­1-(4-methoxyphenyl) pyrazole (26).
  • Example 26 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-[3(Z)-hexadecenyl] pyrazole (33).
  • Example 27 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-[4-phenyl-3(E)-butenyl] pyrazole (14); and 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-[4-phenyl-3(E,Z)-butenyl] pyrazole (15).
  • reaction mixture was diluted to 50 ml with Et2O, washed with H2O, dried (MgSO4), filtered and concentrated in vacuo Chromatography (Baker silica gel, 45 g) with Et2O:hexane (9:1) as eluent, afforded 16 (59%) as a white semi-solid.
  • Example 29 3-[4-(4-Carbomethoxyphenyl)-3(E)-­butenyl]-5-(4-chlorophenyl)-­1-(4-methoxyphenyl) pyrazole (25).
  • Example 31 3-(3-Acetoacetoxypropyl)-5-(4-chlorophenyl)-­1-(4-methoxyphenyl)pyrazole (59).
  • Example 32 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]propylamine (96).
  • Example 34 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-met hyl-N-succinyloxy- propanamide.
  • the compounds of Table 11 were synthesized from compounds 43 or 44 by standard methods..
  • Anti-inflammatory activity of the substituted pyrazole compounds is expressed as the percent inhibition of paw volume increase.
  • the results of this study for several compounds of the structure shown below are shown in Table 16, hereinafter.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1,5-Diaryl-3-substituted pyrazoles, a method of their preparation, compositions containing the same and methods of their use are disclosed. The pyrazoles are useful in alleviating inflammatory and cardiovascular disorders in mammals.

Description

    Technical Field
  • The present invention relates to substituted pyrazole derivatives, and particularly to 1,5-diaryl 3-substituted-pyrazoles that are pharmacologically active in alleviating inflammation, asthma, hypersensitivity, myocardial ischemia, dermatological conditions such as psoriasis, dermatitis and gastrointestinal inflammatory conditions such as inflammatory bowel syndromes, and to a method for synthesizing those pyrazole derivatives.
  • Background
  • Nonsteroidal anti-inflammatory drugs (NSAID's) such as indomethacin, naproxen, ibuprofen, tolectin, fenoprofen and the like have generally been shown to attenuate the biosynthesis of prostaglandins by inhibiting the activity of the enzyme cyclooxygenase. The prostaglandin end-products of the cyclooxygenase pathway are responsible for many of the early signs of inflammation including hyperalgesia, increases in vascular permeability leading to edema, and pyrexia. The activity and potency of the NSAID's in reducing these signs and symptoms is, for the most part, correlated with their ability to inhibit prostaglandin biosynthesis.
  • The other major pathway of arachidonic acid metabolism is the lipoxygenase pathway. Lipoxygenase products of arachidonate metabolism, the leukotrienes, hydroxyeicosatetraenoic acids (HETES) and hydroperoxyeicosatetraenoic acids (HEPTES), have been shown or implicated to be involved in disease states including acute and chronic inflammation, arthritis, allergic and other hypersensitivity disorders, dermatological diseases such as psoriasis, acne, atopic dermatitis, contact sensitivity, eczema and others, cardiovascular disorders secondary to myocardial ischemia or infarction, thromboembolism or vasculitis or platelet aggregation, and hyperalgesic disorders, gynecological disorders such as dysmenorrhea, ocular inflammation, sperm motility or function, and others.
  • Leukotriene B₄ (LTB₄), another product of the lipoxygenase pathway, as well as HETES and HPETES can mediate induction of other phlogistic substances such as thromboxanes and prostacyclin, is chemotactic to inflammatory cells and is hyperalgesic. Many of these mediators have been identified in skin, lungs, coronary circulation, eyes, gastrointestinal tract and other organs, and in the synovial fluid of rheumatoid arthritic patients. In chronic inflammatory conditions such as rheumatoid arthritis, it is believed to be the chronic influx of leukocytes, probably mediated by LTB₄, that is the eventual cause of joint erosion.
  • It is believed that inhibitors of the lipoxygenase pathway could lead to a relatively permanent effect on inflammatory disorders such as rheumatoid arthritis since they could modulate the actual mechanisms of tissue and joint breakdown. Similarly, drugs that could inhibit prostaglandin synthesis via the cyclooxgenase pathway could modulate and reduce early manifestations of inflammation. Pharmacologically active compounds that can inhibit both enzyme pathways at similar concentrations (dual inhibitors) provide a more complete relief for patients suffering from arthritis, hypersensitivity, dermatological, cardiovascular, gastrointestinal, ocular, and gynecological disorders than present drugs that inhibit one pathway, but not the other as is the case for usually used NSAID's that are predominantly inhibitors of the cyclooxygenase (prostaglandin synthesis) pathway.
  • A number of 1,5-diaryl-3-substituted pyrazoles are reported in the literature. Some of these pyrazoles have been reported to have pharmacological activity.
  • For example Fulmer et al., J. Het. Chem., 17:799-800 (1980) report the synthesis of 1,3,5-triaryl pyrazoles, as do Foote et al., J. Het. Chem., 7:89-92 (1970), Beam et al., J. Het. Chem., 9:183-185 (1972); Soliman et al., J. Pharm. Sci., 70:606-610 (1981), and Barluenga et al., J.C.S. Chem. Comm., 891 (1979). Soliman et al., J. Pharm. Sci., 70:602-605 (1981) also report synthesis of 3-methyl-1,5-diarylpyrazoles in which the 1-position aryl is a phenylsulfonylurea or thiourea. Of the above reports, only the two reports by Soliman et al. discuss any pharmacological activity for the pyrazoles prepared or for analogs of those pyrazoles, and those materials are reported to have hypoglycemic activity.
  • Virmani et al., Indian J. Chem., Sect. B, 17B: 472-477 (1979) report the synthesis of 3-omega-alkylaminoalkyl pyrazoles among other compounds. The 1,5-diaryl-3-substituted pyrazoles reported contained a phenyl group at the 1-position, a 4-nitrophenyl at the 5-position, and a (CH₂)n-NHCH₃ group at the 3-position, where n is 3,4 or 5 (3-5). This report stated that the compounds prepared were screened for a number of biological activities, with nine of the ninety-four numbered compounds synthesized having mild anti-inflammatory activity, two others having diuretic activity and two others having weak anti-cancer activity. The above-discussed 1,5-diaryl-3-substituted pyrazoles were not among the compounds reported to have any pharmacological activity.
  • Vereshchagin et al., Zh. Org. Khim., 7:907-912 (1971) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles. The 3-substituents were reported to be alkoxy alkylene in which the alkoxy radical was methoxy or phenoxy and the alkylene was methylene or isopropylene, while the 1,5-diaryl radicals were unsubstituted phenyl.
  • Jahn and Wagner-Jauregg, Arzneim-Forsch. (Drug Res.), 24:494-499 (1974) reported the synthesis and some pharmacological activities of
    1,5-diaryl-3-substituted-4,5-dihydropyrazoles. The aryl group at the 1-position for each reported compound was phenyl, while the 5-aryl substituent was reported to be phenyl, 4-methoxyphenyl, 3-methoxy-4-hydroxyphenyl, and 2-hydroxyphenyl. The before-mentioned pyrazoles were substituted at the 3-position by bonding to the 3-position of propionic acid or propiohydroxamic acid. These compounds were said to possess antirheumatic activity.
  • Shawali et al., J. Het. Chem., 13:989-92 (1976); Shawali, J. Het. Chem., 14:375-81 (1977); and Matsumoto et al., Bull. Chem. Soc. Japan, 47: 946-949 (1979) reported the synthesis of 1,5-diaryl-3-substituted pyrazoles, all of which also included a substituent other than hydrogen at the 4-position on the pyrazole ring. Exemplary 4-position substituents were reported to include cyano, amino, carboethyoxy, and phenylcarbonyl. These reports included no mention of biological activity of the compounds reported.
  • A series of benzimidoylpyrazoles was reported by Shrof et al., J. Med. Chem., 24:1521-1525 (1981). These compounds were reported to possess activities of sulfonyl urea and biguanide hypoglcemics.
  • Biere et al., Arch. Phar., 316:608-616 (1983) reported the synthesis of 1,4-diaryl-pyrazole-3-acetic acid derivatives, some of which also contained a an aryl substituent at the 5-position. The synthesized compounds were assayed for use as anti-inflammatory drugs in rats. The compounds assayed that also contained 5-position substituents were reported to be relatively inactive.
  • A further group of 1,5-diphenyl-4-­substituted-pyrazole-3-acetic acids was reported by El-Sayed and Ohta, Bull. Chem. Soc. Japan, 46:1801-1803 (1973). Those compounds were utilized as intermediates in the synthesis of pyrazolo-[4,3-c]-pyridines. Another group of 1,5-diphenyl-4-substituted-pyrazoles, some of which also include methyl, phenyl and carboxymethyl groups at the 3-position, was reported in Al-Saleh et al., J.C.S. Perkin I, 642-645 (1981). The reports of El-Sayed and Ohta and those of Al-Saleh et al. make no mention of the pharmacological properties of the pyrazole derivatives reported. Another group of 1,5-diaryl-3,4-disubstituted pyrazoles and 4,5-dihydro-5-hydroxy pyrazoles was reported in Fusco and Croce, Gazz. Chim. Ital., 101:703-272 (1971).
  • Summary of the Invention
  • The present invention contemplates 1,5-diaryl-3-substituted pyrazoles, their use and a method of their synthesis. The compounds of the present invention are pharamacologically active in alleviating inflammation, and inhibit the cyclooxygenase enzyme pathway, the lipoxygenase enzyme pathway, or preferably both pathways.
  • In particular, the invention contemplates a substituted pyrazole compound having a structure that conforms to the formula
    Figure imgb0001
        wherein
        R₁, R₂, R₃ and R₄ are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, amino, acetamido, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, ω-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R₁, R₂ or R₃, R₄ taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group;
        R is a straight, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;
        Y is hydrogen, bromo, chloro or lower alkyl having 1-4 carbon atoms;
        and X is selected from the group consisting of carboxy, carboloweralkoxy, hydroxy, acetoxy, alkanoyloxy, lower alkoxy, lower alkyl carbonyl, oximo, cyano, amino, C(O)-R₅ and -C(O)C(O)-R₅ wherein R₅ is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR₆R₇ wherein R₆ and R₇ are the same or different and are selected from the group consisting of hydrogen, and lower alkyl, or R₆ or R₇ are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, hydroxy, lower acyloxy, benzyloxy, 2-hydroxy lower alkyl, lower alkyl carboxy, phenyl, substituted phenyl, pyridyl, thiazolyl, dihydrothiazolyl, ω-alkanoate, 5-tetrazolyl, -OCO(CH₂)nCOR₉ wherein R₉ is -OH, -ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; -OCOR₁₀ wherein R₁₀ is -CH₂NR₁₁R₁₂ wherein R₁₁ and R₁₂ are alkyl, such as methyl, cycloalkyl such as cyclohexyl, or together are a heterocyclic ring such as N-methylpiperazino, -OCOR₁₀ wherein R₁₀ is -CH₂Cl, -CH₂O-loweralkyl or t-butyl, -CH-loweralkyl-CO₂-Q, wherein Q is lower alkyl or -H, acyl such as acetyl, propionyl or butyryl; -NR₈OH wherein R₈ is hydrogen, -CO-loweralkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, SO₂-lower alkyl, -COCO₂-lower alkyl, and -COCONHOH; -NHR₁₃ wherein R₁₃ is hydrogen, -CO-lower alkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, -SO₂-lower alkyl, -COCO₂-lower alkyl, -COCONHOH, -COCO₂H, COCON(lower alkyl)OH, and PO(O-lower alkyl)₂; -C(R₁₄)=NNH-2-thiazolino, -CH(OH)R₁₄ and -C(O)R₁₄ wherein R₁₄ is hydrogen, lower alkyl, phenyl and t-butyl; -C(=NOH)NH₂ and -C(=NH)N(OH)-lower alkyl and O-NR₈R₉ wherein R₈ and R₉ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl;
        with the provisos that:
    • (a) when Y is bromo or chloro, X is -COOH, -CH₂OH or -C(O)-R₅ wheren R₅ is NR₆R₇ and R₆ is -OH and R₇ is lower alkyl;
    • (b) at least one of R₁ and R₂ is other than hydrogen where (i) R-X is (CH₂)₂CO₂H or (CH₂)₂C(O)NHOH and (ii) R₃ and R₄ are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen; and
    • (c) at least one of R₁ and R₂, or one of R₃ and R₄ is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts thereof.
  • In preferred practice, R₂ and R₄ are hydrogen, and R₁ and R₃ are selected from the group consisting of halo, trifluroromethyl, lower alkyl and lower alkoxy, especially methoxy. R preferably contains two carbon atoms. It is also preferred that the X be hydroxyloweralkyl, carboxy, a hydroxamic acid or a N alkyl hydroxamic acid; i.e., that X be C(O)NR₆R₇ where R₆ is hydroxy and R₇ is hydrogen or lower alkyl or a N-alkyl hydroxamic acid; i.e. that x is -C(O)NR₆R₇ wheren R₆ is hydroxy or -OC(O)CH₂Z where Z is dialkylamino or -CH₂CO₂H and R₇ is hydrogen or lower alkyl.
  • The present invention also contemplates a pharmaceutical composition that comprises an anti-inflammatory amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier. The dose may be administered by topical, p.o., parenteral or aerosol routes. In preferred practice, that substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and the lipoxygenase pathways in the amount present in the composition, when the composition is introduced into a mammal.
  • Further contemplated is a method for alleviating inflammation in a mammal exhibiting an inflammatory condition. That method comprises administering to that mammal a pharmaceutical composition that includes as the active ingredient an effective amount of an above-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier for topical, oral, parenteral and aerosol administration.
  • A method for synthesizing a
    1,5-diaryl-3-(omega-substituted lower alkyl)pyrazole is also contemplated. In accordance with this method, an aryl hydrazine or its acid addition salt is reacted with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain. A polar solvent is used that is substantially inert to the reaction conditions, as is the omega-substituent of the alkyl 1,3-dione. The resulting 1,5-diaryl-3-(omega lower alkyl substituted) pyrazole is thereafter preferably recovered, although it can be utilized in the form of its synthesis (crude form), as for further syntheses. Particularly preferred alkyl-1,3-dione derivatives contain 6 carbons in the alkyl chain and contain a hydroxy group as the omega-substituent.
  • The present invention provides several benefits and advantages.
  • A particular benefit of the invention is that it provides pharmacologically active compounds that are useful in treating inflammatory conditions.
  • A particular advantage of the present invention is that its synthetic method provides relatively high yields of 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole compounds.
  • Another benefit of the present invention is that some of its pharmacologically active compounds inhibit the cyclooxygenase enzyme pathway, thereby providing a further means for studying that biological process.
  • Another advantage of the present invention is that some of its pharmacologically active compounds inhibit the lipoxygenase enzyme pathway, thereby providing a further means for studying that biological process.
  • Still further benefits and advantages of the present invention will be apparent to those skilled in the art from the detailed description and Examples that follow.
  • Detailed Description of the Invention
  • 1,5-Diaryl-3-substituted pyrazole compounds, pharmaceutical compositions containing a substituted pyrazole compound as an active ingredient, a method of treating a mammal exhibiting an inflammatory condition and a method of synthesizing the substituted pyrazole compound are contemplated herein.
  • In the above formula, R₁, R₂, R₃ and R₄ are substituents on phenyl rings that substitute for hydrogen atoms at positions 1 and 5 of the pyrazole ring. It is preferred that at least one of R₁ and R₂, and one of R₃ and R₄ be substituted at the 4-positions of their respective phenyl rings.
  • In examining the above structural formula to which the useful pyrazole compounds conform, it is noted that the R₁, R₂, R₃ and R₄ radicals and the X group can be a "lower" alkyl, "lower" alkoxy and the like. Groups and radicals referred to as "lower" denote that they possess 1 to about 6 carbon atoms. The same is true for "lower" groups and radicals that are sustituents of the "lower" groups and radicals enumerated.
  • To the extent that X substituents are defined as being the same as those of R₁, R₂ R₃ and R₄, those commonly defined substituents are discussed immediately below. Additional X substituents that are not common to X and R₁, R₂, R₃ and R₄ are discussed thereafter.
  • Lower alkyl radicals include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, 2-methyl-3-butyl, 1-methylbutyl, 2-methylbutyl, neopentyl, n-hexyl, 1-methylpentyl, 3-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 2-hexyl, 3-hexyl, octyl and the like.
  • Lower alkoxy radicals are oxygen ethers formed from a before-described lower alkyl group. Exemplary radicals include methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, and the like.
  • Lower alkylthio radicals of R₁,R₂,R₃ and R₄ are sulfide ethers and are thus analogous to the oxygen ethers described above.
  • Halo radicals preferably include chloro and bromo, as well as fluoro and iodo.
  • Lower alkylsulfonyl radicals contain a before-described lower alkyl radical bonded to an SO₂ moiety that is itself also bonded to a phenyl ring. Exemplary lower alkylsulfonyl radicals thus include methylsulfonyl, ethylsulfonyl, 2-ethylbutylsulfonyl and the like.
  • An omega-trifluoromethyl lower alkoxy radical is a lower alkoxy radical as before described that additionally includes a trifluoromethyl group at a position farthest on the alkyl chain from the place of bonding to the phenyl ring. Exemplary of such radicals are the 2,2,2-trifluoroethoxy.
  • Naphthyl and substituted naphthyl radicals can replace an aryl group herein at either the 1- or 2-positions to provide 1-naphthyl or 2-napththyl substituents, respectfully. Substituents on the naphthyl radicals can be any of those described herein as being useful aryl substituents. Exemplary substituted 1- and 2-naphthyls include 6-methoxy-2-naphthyl and the like.
  • Lower alkyl carboxy radicals are the before-described lower alkyl radicals that further include a carboxy group. Exemplary lower alkyl carboxy radicals include carboxymethyl, 2-carboxyhexyl and the like. Lower alkyl lower alkoxy carbonyl radicals are lower alkyl esters of lower alkyl carboxy radicals. Exemplary lower alkyl lower alkoxy carbonyl radicals include 3-iso­propoxycarbonylpropyl, 4-hexyloxycarbonylpentyl and the like.
  • A lower alkyl carbonyl radical contains a carbonyl group, a total of up to six carbon atoms, and with the portion of R to which it is linked, forms a ketone at the R/X junction. Exemplary lower alkyl carbonyl radicals include acetyl, propionyl 2-methylpropionyl, pentoyl and the like, which can also be named methyl carbonyl, ethyl carbonyl, isopropylcarbonyl and butylcarbonyl, respectively.
  • Radicals in which X is C(O)-R₅ where in R₅ is lower alkoxy are carboxylic esters. These esters are preferably named by considering R-X to be a single substituent entity. Exemplary R₅ lower alkoxy groups are as before described, although methoxy and ethoxy are preferred. When R₅ is NR₆R₇ and ONR₈R₉, it is also useful to consider R-X as a substituent entity.
  • Lower hydroxy alkyl radicals of R₆ and R₇ are preferably 2-hydroxyethyl and 2-hydroxypropyl. Additionally useful lower hydroxy alkyl radicals include 4-hydroxybutyl and the like.
  • Substituted phenyl radicals that can comprise NR₆R₇ are the same as the substituted aryl groups described before wherein R₁, R₂, R₃ and R₄ comprise the substituents.
  • Pyridyl radicals are derivatives of pyridine and can be bonded to the nitrogen atom of NR₆R₇ at the 2-, 3- or 4-positions relative to the pyridine nitrogen.
  • R in the structural formula above is a straight, saturated or unsaturated hydrocarbyl radical that contains 2 to about 16 carbon atoms. In particularly preferred practice, the R-X radical together contains three saturated carbon atoms linked together by carbon-carbon bonds. In other preferred embodiments, R is unsaturated and contains 7-16 carbon atoms.
  • R is a hydrocarbon radical and therefore contains no elements other than carbon and hydrogen. Consequently, any element present in R-X that is not hydrogen or carbon is, by definition, part of the X radical.
  • Pharmaceutically acceptable, non-toxic acid addition salts of 1,5-diaryl-3-substituted-pyrazole compounds are useful herein, and can be formed by treatment of the pyrazole with an appropriate acid. Exemplary inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric and the like acids. Exemplary organic acids include methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic and the like acids. Conversely, the acid addition salt form can be converted to the free base form by treatment with alkali.
  • 1,5-Diaryl-3-substituted pyrazole compounds can include a carboxylic acid and/or a hydroxamic acid, as already noted. Basic salts of those carboxylic and hydroxamic acids are also contemplated, and are formed by treatment of the acid with an appropriate, non-toxic, pharmaceutically acceptable alkaline reagent to form a carboxylate or hydroxamate cation salt. Exemplary non-toxic, pharmaceutically acceptable cation salts of such carboxylic and hydroxamic acids include sodium, potassium, zinc, aluminum, calcium and magnesium. These salts also readily form in aqueous solutions of the carboxylic and hydroxamic acids.
  • In preferred practice, R₂ and R₄ are hydrogen, and R₁ and R₃ are selected from the group consisting of halo and lower alkoxy, especially methoxy. The preferred R₁ and R₃ substituents are preferably at the 4-positions of their respective aryl (phenyl) rings.
  • It is prefered that R contain two carbon atoms and that X be carboxy, hydroxymethyl, a hydroxamic acid (N-hydroxy amide) or a N-lower alkyl hydroxamic acid (N-hydroxy-N-lower alkyl amide).
  • Specific, particularly preferred 1,5-diaryl-3-substituted pyrazole compounds are named hereinbelow, followed by a parenthesized, underlined numeral for ease of identification and correlation with the syntheses and anti-inflammation study described in detail hereinafter.
  • The preferred species of this invention include:
    • 1. 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxy-N-methylpropanamide, (3)
    • 2. 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-­1-(4-methoxyphenyl) pyrazole, (2)
    • 3. 5-(4-trifluoromethylphenyl)-3-­(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole, (56)
    • 4. 1-(4-bromophenyl)-5-(4-chlorophenyl)-­3-(3-hydroxypropyl) pyrazole, (35)
    • 5. sodium 8-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-5(Z)-octenoate, (32)
    • 6. sodium 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]propanoate, (13)
    • 7. 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-N-tert-butyl-N-­hydroxypropanamide, (57)
    • 8. N-carboxymethyl-3-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl] propanamide, (66)
    • 9. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]-N-hydroxy-N-isopropylpropanamide (81)
    • 10. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]-N-cyclohexyl-N-hydroxypropanamide (82)
    • 11. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]-N-ethyl-N-hydroxypropanamide (83)
    • 12. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]-N-hydroxy-N-phenylpropanamide (84)
    • 13. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]propylamine (96)
    • 14. 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]propanal (11)
    • 15. 5-(4-chlorophenyl)-3-(3-oximino­propyl)-1-(4-methoxyphenyl)pyrazole (26)
    • 16. 3-(3-hydroxypropyl)-1-(4-methoxyphenyl)-5-­(4-tolyl)pyrazole (55)
  • A pharmaceutical composition that comprises an anti-inflammatory amount of a before-discussed 1,5-diaryl-3-substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier is also contemplated herein. The composition comprises a unit dosage of the substituted pyrazole compound.
  • The substituted pyrazole compounds of this invention are capable of inhibiting the lipoxygenase enzyme pathway and/or the cyclooxygenase (prostaglandin synthetase) enzyme pathway. In preferred practice, the substituted pyrazole compound of the pharmaceutical composition is capable of inhibiting both the lipoxyenase and the cyclooxygenase enzyme pathways in the amount at which that substituted pyrazole compound is present in the pharmaceutical composition, when that composition is introduced as a unit dose into an appropriate mammal such as a laboratory rat.
  • The term "unit dosage" and its grammatical equivalent is used herein to refer to physically discrete units suitable as unitary dosages for human patients and other warm blooded animals, each unit containing a predetermined effective, pharmacologic amount of the active ingredient calculated to produce the desired pharmacological effect in association with the required physiologically tolerable carrier, e.g., a diluent or a vehicle. The specifications for the novel unit dosage forms of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active ingredient, and (b) the limitations inherent in the art of compounding such an active ingredient for therapeutic use in humans and other animals. Examples of suitable unit dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, and the like, segregated multiples of any of the foregoing, as well as liquid solutions and suspensions.
  • The active ingredient is referred to herein as being dispersed in the carrier. Thus, the dispersion formed can be a simple admixture, a non-settling dispersion as in the case of certain emulsions, or as an ultimate dispersion, a true solution.
  • The amount of active ingredient that is administered in vivo depends on the age and weight of the mammal treated, the particular medical condition to be treated, the frequency of administration, and the route of administration. The dose range can be about 0.01 to about 500 milligrams per kilogram of body weight, more preferably about 0.1 to about 50 milligrams per kilogram of body weight and most preferably about 0.1 to about 25 milligrams per kilogram of body weight. The human adult dose is in the range of about 10 to about 2000 milligrams daily, given as a single dose or in 3 or 4 divided doses. Veterinary dosages correspond to human dosages with the amounts administered being in proportion to the weight of the animal as compared to adult humans.
  • As is seen from the data discussed hereinafter, orally administered unit doses containing about 1 to about 50 milligrams of a 1,5-diaryl-3-substituted pyrazole per kilogram of laboratory rat body weight (e.g., about 200 grams each) were useful in reducing inflammation. These results are contrary to those reported by Virmani et al., Indian J. Chem., Sect. B, 17:472-477 (1979) who reported compounds that are structurally similar to those described herein were not active as anti-inflammatory agents.
  • Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are aqueous solutions that contain no materials in addition to the substituted pyrazole compound, or contain a buffer such as sodium phosphate at physiological pH value, saline and the like.
  • Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin and vegetable oils such as cottonseed oil.
  • Exemplary solid carriers (diluents) include those materials usually used in the manufacture of pills or tablets, and include corn starch, lactose, dicalcium phosphate, thickeners such as tragacanth and methylcellulose U.S.P., finely divided SiO₂, polyvinylpyrrolidone, magnesium stearate and the like. Antioxidants such as methylparaben and propylparaben can be present in both solid and liquid compositions, as can sweeteners such a cane or beet sugar, sodium saccharin, sodium cyclamate and the dipeptide methyl ester sweeteneer sold under the trademark NUTRASWEET (aspartame) by G. D. Searle Co.
  • A method for alleviating inflammation in a mammal exhibiting an inflammatory condition is also contemplated. The method comprises administering to that mammal an effective amount of a pharmaceutical composition that includes a unit dose of an active ingredient that is the before-described substituted pyrazole compound dispersed in a pharmaceutically acceptable carrier. The pharmaceutical composition is preferably maintained within the mammal until the substituted pyrazole compound is cleared from the mammal's body by natural means such as excretion or metabolism.
  • The pharmaceutical composition can be administered orally, topically or by injection, by means well known in the art. In preferred practice, the composition is administered orally as a tablet, capsule or aqueous dispersion.
  • Inasmuch as a pharmaceutial composition can be administered 3 to 4 times daily (per 24 hour period), the method of alleviating inflammation can include administering the pharmaceutical composition a plurality of times into the treated mammal over a time period of weeks, months and years. The pharmaceutical composition is administered a plurality of times to the mammal over a time period of thirty days, in preferred practice.
  • A method for synthesizing a 1,5-diaryl-(omega-substituted lower alkyl) pyrazole constitutes yet another aspect of the present invention. Here, an aryl hydrazine or its acid addition salt is admixed in an inert polar solvent with a 1-aryl-(omega-substituted)-alkyl-1,3-dione containing at least 4 carbons, and up to about 9 carbon atoms, in the alkyl chain to form a reaction mixture. The aryl hydrazine and the 1,3-alkyldione are preferably reacted in substantially stoichiometric amounts.
  • The omega-substituent of the 1-aryl-omega-­substituted-alkyl-1,3-dione is substantially inert to the reaction conditions utilized for the cyclization reaction; i.e., the substituent does not itself react with any of the reactants or solvent during the cyclization reaction. Exemplary of useful substituents are hydroxy and lower alkoxy as before described. Hydroxy is particulary preferred as the omega substituent.
  • The aryl hydrazine and aryl-alkyl-1,3-dione are reacted in an inert polar solvent medium. Exemplary of such solvents are methanol, ethanol, isopropanol, pyridine, triethylamine and mixtures of those solvents.
  • The reaction mixture so formed is maintained with agitation, as by stirring, for a predetermined period of time for the 1-aryl-hydrazine and the 1-aryl-(omega-substituted)-alkyl-1,3-dione to react and form the desired 1,5-diaryl-3-(omega-substituted lower alkyl) pyrazole. The predetermined time period is typically about 1 to about 20 hours, depending upon the reactants, solvent and reaction temperature.
  • The cyclization reaction is normally carried out at ambient room temperature. The temperature typically rises somewhat during the cyclization, but is readily controlled. Temperatures above room temperature can also be utilized.
  • The resulting substituted pyrazole can be used as is in its crude form directly after the cyclization, as where a further reaction is to be carried out with it. Preferably however, the crude reaction product formed is recovered and purified as by crystallization or column chromatography prior to use in a further reaction or to alleviate inflammation.
  • Further reactions can be carried out on the omega-substituent of the pyrazole-3-lower alkyl group inasmuch as that substituent is substantially inert to the reaction conditions for cyclization and formation of the pyrazole ring, but need not be inert to all reaction conditions.
  • An exemplary, generalized reaction sequence is shown below in Scheme 1 where a 1-(R₃,R₄-­disubstituted phenyl)-6-hydroxy-hexan-1,3-dione and R₁,R₂-disubstituted phenyl hydrazine hydrochloride are reactants (A) and (B), respectively, that react to form 1-(R₁,R₂-disubstituted phenyl)-5-(R₃,R₄-­disubstituted phenyl)-3-(3-hydroxypropyl)-pyrazole, I, wherein R₁,R₂,R₃ and R₄ are as previously defined. The parenthesized numerals beneath the structual formula of I refer to compounds of that structure that are exemplified hereinafter.
  • The reaction sequence shown thereafter in Scheme 2 relates to reactions carried out with specific compounds and in which R* is the 1-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl]methylene group (as shown hereinafter); R₁-R₇ are as before described; lower case letters adjacent to reaction arrows indicate reaction conditions discussed thereafter below; and underlined numerals indicate specific compounds whose syntheses are described in detail hereinafter.
    Figure imgb0002
    Figure imgb0003
    a, pyridinium chlorochromate; b, Jones Reagent; c, lithium hexamethyldisilazide/BrPh₃P(CH₂)₄ CO₂H; d, oxalyl chloride; e, R₆NHOH; f, R₆R₇NH.
    Figure imgb0004
  • Treatment of the appropriate aryl diketone A wherein R₃ and R₄ are defined as before with arylhydrazine B wherein R₁ and R₂ are defined as before gives the 1,5-diarylpyrazoles I that are isolated by recrystallization or chromatography on silica from the corresponding 1,3-diarylpyrazoles formed as minor products of the reaction.
  • The pyrazoles of formula I are oxidized to either the acid (e.g., 12) with, for example, Jones Reagent or to the aldehyde (e.g., 11) with, for example, pyridinium chlorochromate, as illustrated with compound 2; i.e., 5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-­(4-methoxyphenyl)pyrazole. The olefinic acid 32 was obtained by treatment of aldehyde 11 with (4-carboxylbutyl)triphenylphosphorane.
  • The appropriate acid chlorides were synthesized by treatment of acids of general formula 12 or 32 with oxalyl chloride in tetrahydrofuran (THF). The acid chlorides were then added as THF solutions to a solution of the appropriate alkylhydroxylamine hydrochloride [R₆NHOH(HCl)] in THF/water/triethylamine (THF/H₂O/Et₃N) to afford the alkylhydroxamic acids such as compounds 3, 58 and 41. The corresponding O-acylated products (e.g., 53 and 57) that may also form in the reaction were separated by either recrystallization or chromatography.
  • Similarly, treatment of the acid chlorides above with amines of general formula R₆R₇NH gave amides such as 28, 65 and 38, where R₆ and R₇ are as before defined.
  • Oxidation of compound 65 with Jones Reagent as above gave acid 66.
  • The remaining compounds of this invention were synthesized by standard methods from pyrazole alcohol 2, aldehyde 11 or acid 12 as shown in Scheme 3, below. The substituted pyrazole compounds with unsaturated side chains at the 3-position were prepared by reaction of aldehyde 11 with the appropriate Wittig reagent, as discussed specifically hereinafter and shown in Scheme 2, above. R₁-R₇, lower case letters and underlined numerals are as described for Schemes 1 and 2, before. R* in Scheme 3 is the 1-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl-ethylene group, as shown.
    Figure imgb0005
    a₁, acetic anhydride/pyridine, a₂, 2,2,6-trimethyl-1,3-­dioxen-4-one; b, NaH, methyl iodide; c, CH₂N₂; d, NH₂OH; e, methyl magnesium bromide; f, pyridinium chlorochromate; g, lauryltriphenyl phosphonium bromide [BrPh₃P(CH₂)₁₁CH₃] benzyltriphenylphosphonium chloride [PhCH
    Figure imgb0006
    PPh₃Cl⁻];
    (4-methoxycarbonylphenyl)-triphenylphosphonium chloride [4-CO₂MePhCH₂P⁺Ph₃Cl⁻].
    Figure imgb0007
  • Best Modes for Carrying Out the Invention
  • Melting point (mp) were determined on a Thomas-Hoover apparatus, and are uncorrected. The infrared (IR) spectra were recorded on a Beckman Instruments IR-8 spectrophotometer and are expressed in reciprocal centimeters. Nuclear magnetic resonance (NMR) spectra for hydrogen atoms were measured in the indicated solvent with tetramethylsilane (TMS) as the internal standard on a Varian T-60A or an IBM WP-100 spectrometer. The values are expressed in parts per million downfield from TMS. Parenthesized, underlined hydrogens were assigned to the resonance positions immediately before the parentheses. EI and CI mass spectra were obtained on a Finnigan 1015D quadrupole mass spectrometer coupled to a Finnigan 9500 gas chromatograph or a Finnigan MAT 8230 Double Focusing high resolution mass spectrometer.
  • Example 1: 5-(4-Chlorophenyl)-3-(3-hydroxypropyl)-­1-(4-methoxyphenyl) pyrazole (2).
  • 4-Methoxyphenylhydrazine hydrochloride [35.0 grams (g), 0.20 moles] was added to CH₃OH [50 milliters (ml)] containing pyridine (20 ml). An additional amount of CH₃OH (25 ml) was added to the thick resulting slurry. 1-(4-Chlorophenyl)-6-
    hydroxyhexan-1,3-dione (48.2g, 0.20 moles), was added neat, followed by more CH₃OH (25 ml). The slurry was stirred at room-temperature for 1.5 hours, after which times the mixture was concentrated and taken up in CHCl₃ (300 ml). The CHCl₃ solution was washed with 1N HCl (300 ml), dried (Na₂SO₄), filtered, and concentrated. The oil was decolorized (Norit) in hot diethyl ether (Et₂O) (300 ml). The Et₂O solution was cooled, and crystallization from Et₂O (300 ml) afforded 2 (49.4 g). From the filtrate was obtained additional 2 (9.28 g), total yield 91%, mp 87.5 - 88°. NMR (CDCl₃) 1.7 - 2.3 (m, 2H, CH₂CH₂CH₂), 2.55 (brs, 1H, OH), 2.80 (t, 2H, J=7Hz, CH₂), 3.75 (t, 2H, J=6Hz, CH₂O), 3.77 (s, 3H, OCH₃), 6.28 (s, 1H, C₄-H), 6.93 (ABq, 4H, J=12, 9, 4-OMe-C₆H₄), 6.9 - 7.3 (m, 4H, 4-Cl-C₆H₄); IR (KBr) 3320, 2920, 1495; MS, m/e 342 (M+), 312, 298 (100%);
    Anal. Calcd. for C₁₉H₁₉ClN₂O₂:C,66.56,H,5.59;N,8.17
          Found:C,66.54;H,5.76;N,8.02
  • The following general procedure was used for the preparation of 1,5-diaryl-3-(3-hydroxypropyl) pyrazoles of Tables 1 and 2 that follow.
  • The appropriate aryl hydrazine or hydrazine hydrochloride B [10 millimoles (Mm)] was dissolved in a solution of methanol (25 ml) containing pyridine (1 ml). The appropriately substituted 1-aryl-1,3-dione A (10 Mm) was admixed in a single portion. In a short time, the mixture warmed slightly, darkened, and became homogeneous. After stirring at ambient temperature for a time period of from 2 to 20 hours, the reaction mixture was worked up as follows: the mixture was concentrated in vacuo and taken up in diethyl ether (250 ml); the ether solution was washed with aqueous 1N HCl (200 ml), decolorized, dried (Na₂SO₄), filtered through a pad of celite, and concentrated in vacuo. The crude material was either purified by column chromatography (silica gel 60, 70 - 230 mesh, about 250 g, and elution with ether) to give the desired 1,5-diarylpyrazoles (I) or recrystallized directly without chromatography. In some cases the isomeric 1,3-diaryl isomer was also isolated in varying minor amounts, and eluted before I from the column.
    Figure imgb0008
    Figure imgb0009
    Figure imgb0010
  • Compounds in which R₁, R₂, R₃ and R₄ are all other than hydrogen can be synthesized by the above procedure. For example, when the aryl hydrazine B is 3,4-dimethoxyphenylhydrazine and the 1-aryl-1,3-dione A is 3,4-dichloro-4,6-dioxohexanoic acid, 5-(3,4-dichlorophenyl)-­1-(3,4-dimethoxyphenyl)-3-(3-hydroxypropyl)-pyrazole is obtained.
    Figure imgb0011
    Figure imgb0012
  • Example 2: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propionic acid (12).
  • To a solution of the alcohol 2 [(0.92 g, 2.68 millimoles (mM)] in acetone (25 ml) was added a 2N H₂Cr₂O₇ (Jones Reagent) solution (3.02 ml, 6.04 mM) dropwise over a 10 minute time period. After stirring for 1 hour the reaction solution was decanted from the chromium precipitates on the sides of the reaction vessel. The reaction solution was concentrated in vacuo and taken up into ethyl acetate (EtOAc) (100 ml), washed with distilled H₂O until the washes were clear, dried (MgSO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O: hexane afforded 12 (0.88 g, 92%) as an off-white crystalline solid, mp = 126 - 128°C.
        NMR: (CDCl₃) 2.7 - 3.2 (m, 4H, -CHCH₂-), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic), 7.5 - 8.5 (1H, -COOH); IR (KBr) 1700; MS, m/e 356 (M⁺), 312, 311 (100%).
    Anal. Calcd. for C₁₉H₁₇ClN₂O₃: C,63.95;H,4.80;N,7.85
          Found: C,63.82;H,4.92;N,7.72.
  • Example 3: Sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazoyl] propanoate monohydrate (13).
  • To the acid 12 (1.0169 g, 2.85 mM) was added a 1.00 N NaOH solution (2.85 ml, 2.85 mM) and distilled H₂O (15 ml). The reaction mixture was stirred until it was homogeneous, and then lyophilized to afford 13 (1.08 g, 98%) as a white solid, with a mp greater than 300°C.
        NMR (CD₃OD) 2.3 - 3.2 (m, 4H, -CH₂-­CH₂-), 3.80 (s, 3H, -OCH₃) , 6.47 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 3250, 1640.
    Anal. Calcd. for C₁₉H₁₆ClN₂NaO₃.H₂O:C,57.51;H,4.57;N,7.06
          Found: C,57.19;H,4.33;N,6.98.
  • Example 4: 3-[5-(4-Chlorophenyl)-1-phenyl-3-pyrazolyl] propionic acid (17).
  • Following the procedure for compound 12 but substituting compound 1 for 2 afforded 17 (0.86 g, 68%) as a white crystalline solid, mp = 138 - 139°C.
        NMR (CDCl₅) 2.6 - 3.2 (m, 4H, -CH₂-CH₂-), 6.30 (s, 1H, C₄-H); 6.4 - 7.5 (m, 10H, aromatic and -COOH). IR (KBr) 3460, 1740; Ms, m/e 326 (M⁺), 282, 281 (100%).
    Anal. Calcd. for C₁₀H₁₅ClN₂O₂:C,66.16:H,4.63;N,8.57
          Found;C,66.48;H,4.72;N,8.59.
  • Example 5: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxy-N-methylpropanamide (3).
  • To a solution of the acid 12 (0.99 g, 2.77 mM) in tetrahydrofuran (THF) (20 ml) at 0°C, was added one drop of dimethyl formamide (DMF) and oxalyl chloride (0.29 ml, 33 mM). After 0.5 hours the cooling bath was removed and stirring was continued for an additional 0.5 hours. The reaction mixture was concentrated in vacuo to remove any excess oxalyl chloride, and the acid chloride of 12, was taken up into THF (10 ml).
  • To a solution of methylhydroxylamine hydrochloride (0.35 g, 4.16 mM) and triethylamine (Et₃N) (1.55 ml, 11.10 mM) in THF, H₂O (10 ml:5 ml) at 0°C, was added the THF solution of the acid chloride dropwise over a 5 minutes period. The cooling bath was removed, and the reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H₂O, dried (MgSO₄), filtered, and concentrated in vacuo. Chromatography (Baker silica gel, 45g) of the residue with EtOAc as eluent, followed by crystallization from Et₂O afforded pure 3 (0.70 g, 65%), mp = 113 - 115°C. Further recrystallization from ethyl acetate afforded white crystalline solid, m.p. 125-26°C.
        NMR: (CDCl₃) 2.7 - 3.5 (m, 4H, -CH₂CH₂-), 3.18 (broad s, 3H, -N-CH₃), 3.83 (s, 3H,-OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic), 10.67 (broad s, 1H, -N-OH); IR (KBr) 3160, 1640; MS, m/e 385 (M⁺), 339 (100%).
    Anal. Calcd. for C₂₀H₂₀ClN₃O₃:C,62.25:H,5.22:N,10.89
          Found:C,62.60;H,5.18;N,10.82.
    Figure imgb0013
    Figure imgb0014
  • The following general procedure was used for the preparation of the
    1,5-diaryl-3-pyrazole propionic acids of Table 2ʺ.
  • A mixture of the appropriate
    6-aryl-4,6-diketohexanoic acid (0.1 Mole) from Table 2ʺ -AP in methanol (750 ml) containing Et₃N (0.2 Mole) was treated with 4-methoxyphenylhydrazine hydrochloride (17.4 g, 0.1 Mole) at room temperature for 1 hour. If the reaction was incomplete at this point, it was refluxed until complete. The resulting darkened solution was evaporated in vacuo and taken up in Et₂O (700 ml); the ether solution was washed with aqueous 1N HCl (350 ml), brine, dried (Na₂SO₄), decolorized, evaporated in vacuo and recrystallized from Et₂O.
  • The compounds of Table 2ʺ were synthesized directly from the appropriate 4,6-diketohexanoic acid as described below.
  • Synthesis of 6-Aryl-4,6-diketohexanoic acids.
  • The compounds of Table 2ʺ -AP were synthesized by the following general procedure. To a reaction vessel containing anhydrous THF (250 ml) and diisopropylamine (14 ml, 0.1 Mole) stirring under nitrogen at 0°C was added by syringe, n-BuLi (1.6 M, 62.5 ml,0.1 Mole). The vessel was then cooled to -78°C. Alternatively, lithium hexamethyldisilazide (0.1 Mole) may be employed as the base in place of lithium diisopropylamide.
  • The appropriately substituted acetophenone (0.1 Mole) in anhydrous THF (50ml) was added and the resulting solution allowed to stir for 30 minutes at -78° and succinic anhydride (4.0 g, 0.04 mole) in THF (100 ml) was added via syringe. The solution was allowed to stir for 1 hour at -78°, warmed to room temperature for 1 hour and poured into 5% HCl (250 ml). The mixture was extracted with Et₂O (2 × 300ml) and the combined ether extract was extracted with 10% NaOH (100 ml). The NaOH layer was separated and acidified with 4N HCl, and reextracted with Et₂O (2 × 300 ml). The combined ether layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The resultant residues were recrystallized from the appropriate solvent to give the compounds of Table 2ʺ -AP.
  • Example 6: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxy-N-methylpropanamide sodium salt monohydrate(3a)
  • To hydroxamic acid 3 (0.6052 g, 1.57 mM) was added 1.00 N NaOH solution (1.57 ml, 1.57 mM) and distilled H₂O (3 ml). The reaction mixture was stirred for 10 minutes at which time it was homogeneous. Lyophilization afforded pure 3a (0.64 g, 97%) as a white hygroscopic solid, mp = 100 - 110°C (decomposed).
        NMR: (CD₃OD) 2.3 - 3.4 (m, 4H, -CH₂CH₂-), 2.92 (broad s, 3H, -NCH₃), 3.78 (s, 3H, -OCH₃), 6.47 (s, 1H, C₄-H), 6.7 - 7.6 (m, 8H, aromatic); IR (KBr) 3420, 1600; MS, m/e 384 (M-Na).
    Anal. Calcd. for C₂₀H₁₉ClN₃NaO₃.H₂O:C,56.40;H,4.97;N,9.87
          Found;C,56.24;H,4.53;N,9.70.
  • Example 7: 0-[2-[5-(4-Chlorophenyl)-1(4-­methoxyphenyl)-3-pyrazolyl] ethyl-carbonyl]-­N-methylhydroxylamine (53).
  • The procedure to synthesize compound 3 was repeated on a twenty-fold scale.
  • Chromatography of the crude reaction mixture (Merck Silica Gel 60; 230 - 400 mesh, 150 g) with CH₃OH:CHCl₃ (3 ;97) as eluent, separated 3 from a mixture with the less polar component (2.5 g, Rf = 0.18).
  • Chromatography (Merck Silica Gel 60; 230 - 400 mesh, 75 g) of this mixture with Et₂O as eluent, and crystallization from Et₂O: hexane afforded 53(0.81 g, 3.7%) as a white crystalline solid, mp = 80 - 81°C (sharp).
        NMR: (CDCl₃) 2.83 (d, 3H, J = 7.5 Hz, -NHCH₃) , 2.6 - 3.3 (m, 4H, -CH₂CH₂-, 3.83 (s, 3H, -OCH₃), 6.33 (s, 1H, C₄-H), 6.7 - 7.4 (m, 4H, aromatic), 7.55 (q, J = 7.5 Hz, 1H, -NHCH₃); IR (KBr) 3200, 1740; MS (20 eV EI), m/e 356, 339 (100%), 311, 297. Anal. Calcd. for C₂₀H₂₀ClN₃O₃:C,62.25;H,5.22;N,10.89
          Found; C,62.31;H,5.21;N,10.88.
  • Example 8: N-Carboxymethyl-3-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl]­propanamide (66).
  • Following the procedure of Example 5, but substituting glycine for methylhydroxylamine hydrochloride afforded 66 (1.98 g, 67.4%), as a white crystalline solid, melting point = 185.5 - 187.5°C.
        NMR (DMSO-d₆) 2.4 - 2.7 (m, 2H, -CH₂CH₂CON-), 2.7 - 3.0 (m, 2H, -CH₂CH₂CON-), 3.78 (s, 3H, -OCH₃), 3.78 (d, J = 5.5 Hz, 2H, -NHCH₂COOH), 6.53 (s, 1H, C₄-H), 6.7 - 7.6 (m, 8H, aromatic), 8.29 (broad t, J = 5.5 Hz, 1H, CONH-CH₂COOH) ; IR (KBr) 3360, 1725, 1665; MS, m/e 413 (M⁺), 311 (100%).
    Anal. Calcd. for C₂₁H₂₀ClN₃O₇:C,60.94;H,4.87;N,10.15
          Found:C,60.64;H,4.87;N,10.01.
  • Example 9: 3-[5-(4-Chlorophenyl)-1-phenyl-3-pyrazolyl]-­N-hydroxy-N-methyl propanamide (67).
  • Following the procedure described in Example 5 but substituting compound 17 for compound 12 afforded 67 (1.24 g, 78.0%) as a white crystalline solid, mp = 155 ­156.5°C.
        NMR (CDCl₃) δ 2.5 - 3.5 (m, 4H, -CH₂CH₂-), 3.20 (s, 3H, -N(CH₃)OH), 6.33 (s, 1H, C₄H), 7.0 - 7.7 (m, 9H, aromatic). 10.37 (broad s, 1H, -N(CH₃) OH); IR (KBr): 3120, 1650; MS, m/e 355 (M⁺), 309 (100%).
    Anal. Calcd. for C₁₉H₁₈ClN₃O₂:C,64.13;H,5.10;N,11.81
          Found:C,64.17;H,5.45;N,11.51.
  • Example 10: 3-[5-(4-Fluorophenyl)-1-(4-methoxyphenyl)- 3-pyrazolyl]-N-hydroxy-N-methyl propanamide (45).
  • Following the procedure described in Example 5, but substituting compound 30 for compound 12 afforded 45 (1.21 g, 83%) as an off-white crystalline solid, mp = 151 - 154°C.
        NMR (CDCl₃) 2.7 - 3.5 (m, 4H, -CH₂CH₂-), 3.20 (broad s, 3H, -NCH₃), 3.83 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic) 10.4 - 10.9 (broad s, 1H, -NOH); IR (KBr): 3140, 1650; MS (20 eV EI, m/e 369 (M⁺), 340, 323 (100%).
    Anal. Calcd. for C₂₀H₂₀FN₃O₃:C,65.03;H,5.46;N,11.38
          Found:C,64.87;H,5.59;N,11.05.
  • Example 11:
  • Following the procedure described in Example 5, the following compounds were synthesized.
    Figure imgb0015
  • Example 12: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxypropanamide (29).
  • To a solution of the acid 12 (0.97 g, 2.72 mM) in THF (20 ml) at 0°C, was added one drop of DMF (catalyst) and oxalyl chloride (0.28 ml, 3.26 mM). After 0.5 hour the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to remove any excess oxalyl chloride, and the remaining crude acid chloride, of acid 12, was taken up in THF (10 ml).
        To a solution of hydroxylamine hydrochloride (0.28 g, 4.08 mM) and Et₃N (1.52 ml, 10.9 mM) in THF:H₂O (10 ml:5 ml) at 0°C, was added the crude acid chloride solution, dropwise over a 5 minutes period. The cooling bath was removed, and the reaction mixture was stirred for 1 hour, diluted to 100 ml volume with EtOAc, washed with H₂O, dried (MgSO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O afforded 29 (0.88 g, 87%) as a white crystalline solid, mp = 154 - 156°C.
        NMR (CDCl₃) 2.4 - 3.4 (m, 4H, -CHCH₂-), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.3 - 7.5 (m, 9H, aromatic and -NH-). IR (KBr): 3260, 1665; MS, m/e 371 (M⁺), 353, 339, 311, 298 (100%).
    Anal. Calcd. for C₁₉H₁₈ClN₃O₃:C,61.37;H,4.88;N,11.30
          Found:C,61.36;H,5.05;N,10.97.
  • Example 13: 0-[2-[5-(4-Chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl] ethylcarbonyl]-N-tert-butylhydroxylamine (57); and 3-[5-(4-chlorphenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-­N-tert-butyl-N-hydroxypropanamide (58).
  • To a solution of the acid12 (0.99 g, 2.77 mM) in THF (30 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.29 ml, 3.33 mM). After stirring for 0.5 hour the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to a volume of 10 ml, and added dropwise to a solution of N-(tert-butyl) hydroxylamine (HCl) (0.52 g, 4.16 mM) and Et₃N (1.56 ml, 11.1 mM) in THF:H₂O (12 ml:6 ml) at 0°C. The reaction mixture was stirred for 1 hour, diluted to 100 ml with EtOAc, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo. The residue was combined with that from a similar run on a 2.72 mM scale.
  • Chromatography (Merck Silica Gel 60; 230 - 400 mesh, 72 g) with Et₂O:hexane (4:1) as eluent afforded 57, crystallized from cold Et₂O:hexane (1.19 g, 51%) as a white crystalline solid, mp = 73 -74.5°C and 58 recrystallized from EtOAc:Et₂O (0.63g, 27%) as a white crystalline solid, mp = 137 - 138°C.
  • Compound 57, NMR (CDCl₃) 1.10 (s, 9H, -C(CH₃)₃), 2.7 - 3.4 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 6.32 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic); IR (KBr) 3480, 1730; MS (20eV EI), m/e 339 (100%), 311, 297.
    Anal. Calcd. for C₂₃H₂₆ClN₃O₃:C,64.55;H,6.12;N,9.82       Found:C,64.41;H,6.19;N,9.71.
  • Compound 58, NMR (CDCl₃) 1.25 (s, 9H, -C(CH₃)₃), 2.7 - 3.4 (m, 4H, -CH₂CH₂-), 3.83 (s, 3H, -OCH₃), 6.33 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic), 10.08 (s, 1H, -N-OH). IR (KBr) 3460, 3130, 1620, 1590; MS (20eV EI), m/e 427 (M⁺), 339 (100%), 311, 297.
    Anal. Calcd. for C₂₃H₂₀ClN₃O₃:C,64.55;H,6.12;N,9.82
          Found:C,64.62;H,6.38;N,9.72.
  • Example 14: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propanal (11).
  • To a suspension of pyridinium chlorochromate (10.02 g, 46.5 mM) in CH₂Cl₂ (500 ml) was added the alcohol 2, (5.09 g, 15.5 mM). After stirring overnight, the reaction mixture was concentrated in vacuo to a volume of about 200 ml, and diluted to 1 liter with Et₂O. This solution was filtered through celite, and the filter cake was washed with Et₂O (2 × 200 ml). The filtrate and the washes were combined and concentrated in vacuo. Chromatography (120g, Baker silica gel) of the residue with Et₂O:hexane (2:1) as eluent, and crystallization from Et₂O afforded pure 11,0.88 g, 17%) as a white crystalline solid, mp = 101 - 102°C.
        NMR (CDCl₃) 2.8 - 3.2 (m, 4H, -CH₂CH₂CHO), 3.85 (s, 3H, -OCH₃), 6.32 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic), 9.93 (t, J = 1Hz, 1H, -CHO); IR (KBr) 1715; MS, m/e 340 (M⁺), 312 (100%).
    Anal. Calcd. for C₁₉H₁₇ClN₂O₂:C,66.96;H,5.03;N,8.22
          Found:C,66.72;H,5.12;N,8.13.
  • Example 15: Sodium 8-[5-(4-Chlorophenyl)-1-(4-­methoxyphenyl)-3-pyrazolyl]-5(Z)-­octenoate (32).
  • To a solution of hexamethyldisilazane (5.25 ml, 24.9 mM) in THF (125 ml) at +5°C was added 1.46 M n-butyl lithium (n-BuLi) (16.3 ml, 23.8 mM). The cooling bath was removed after 15 minutes and (4-carboxybutyl)­triphenylphosphonium bromide (5.17 g, 11.7 mM) was added. Stirring was continued for 45 minutes and the aldehyde 11 (3.61 g, 10.6 mM) was added. After stirring for 1 hour, the reaction solution was diluted to a 600 ml volume with EtOAc and extracted with H₂O (2 × 200 ml). The extracts were combined, acidified with 3N HCl, and extracted with EtOAc (2 × 200 ml). The EtOAc extracts were combined, dried (Na₂SO₄), filtered and concentrated in vacuo. Chromatography of the remaining residue (Baker silica gel, 160 g) with Et₂O as eluent afforded the acid (3.39 g, 75%) as a clear yellow oil.
  • To the neat acid (0.57 g, 1.34 mM) was added a 1.00 N NaOH solution (1.34 ml, 1.34 mM) and a small amount of water. After stirring overnight, the reaction solution was lyophilized to afford 32 (0.60 g, 95%) as a white solid.
        Acid, NMR (CDCl₃) 1.4 - 3.1 (m, 10H, -CH₂CH₂CH=CH(CH₂)₃ COOH), 3.80 (s, 3H, - OCH₃), 5.2 - 5.7 (m, 2H, -CH=CH-), 6.33 (s, 1H, C₄-H), 6.7 - ­7.5 (m, 8H, aromatic); MS (20 eV EI) , m/e 426 (M+2), 424 (M⁺), 365, 351, 337, 298 (100%).
        Compound 32, NMR (CD₃OD) 1.4 - 3.1 (m, 10H, -CH₂CH₂CH=CH(CH₂)₃-), 3.80 (s, 3H, -OCH₃), 5.2 - ­5.7 (m, 2H, -CH=CH-) , 6.45 (s, 1H, C₄-H), 6.7 - 7.5 (m, 8H, aromatic); IR (KBr) 3440, 1565; MS, m/e 423 (M-Na).
    Anal. Calcd. for C₂₄H₂₄ClN₂NaO₃(1.25 H₂O):C,61.40;H,5.69;N,5.97
          Found:C.61.60;H,5.46;N,5.51.
  • Example 16: 8-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N-hydroxy-N-methyl-­5(Z)-octenamide (41).
  • Following the procedure described in Example 5, but substituting the acid for 12 afforded 41 (0.94 g, 62%) as a clear colorless oil.
        NMR (CDCl₃) 1.5 - 3.5 (m, 14H, -(CH₂)₂-CH=CH-(CH₂)₃CON(CH₃)OH, 3.80 (s, 3H, -OCH₃), 5.3 - 5.7 (m, -CH=CH-, 2H), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat): 3160, 1630; MS (20 eV EI), m/e 455 (M+2), 453 (M⁺), 407, 379, 365, 298 (100%).
    Anal. Calcd. for C₂₅H₂₈ClN₃O₃:C,66.14;H,6.22;N,9.26
          Found:C,65.78;H,6.55;N,8.93.
  • Example 17: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-N,N-diethylpropanamide (28).
  • To a solution of the acid 12 (1.01 g, 2.83 mM) in THF (25 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.30 ml, 3.40 mM). After 0.5 hours the cooling bath was removed and stirring was continued for 0.5 hour. The reaction mixture was concentrated in vacuo to remove the excess oxalyl chloride, and the remaining acid chloride was diluted with THF (25 ml) and cooled to 0°C. To this solution diethylamine (1.17 ml, 11.32 mM) was added dropwise over a 5 minute period. After stirring for 1 hour, the reaction mixture was diluted to 100 ml with Et₂O, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo. Crystallization from Et₂O afforded 28 (0.98 g, 84%) as a yellow crystalline solid, mp = 111 - 112°C.
        NMR (CDCl₃) 1.13, 1.17 (2t, J = 7Hz, 6H, -N(CH₂CH)₂), 2.5 - 3.8 (m, 8H, -CH₂CH₂- and -N(CH₂CH₃)₂), 3.80 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 1630; MS (20eV EI), m/e 411 (M⁺), 311 (100%).
    Anal. Calcd. for C₂₃H₂₆ClN₃O₂:C,67.06;H,6.36;N,10.20
          Found:C,67.14;H,6.34;N,9.95.
  • Example 18: Compounds of Table 3.
  • Following the procedure of Example 17, but substituting NH₄OH, 4-aminophenol,
    O,N-dimethylhydroxylamine hydrochloride, 2-aminophenol, 2-aminothiophenol, 2-aminopyridine and ethanolamine for diethylamine gave the compounds of Table 3.
    Figure imgb0016
    In addition, following the procedure of Example 17, the following were synthesized.
    Figure imgb0017
  • Example 19: Compounds of Table 4.
  • Following the procedure of Example 17 but substituting the acid for 12 and allowing the resulting acid chloride to react with NH₄OH and diethylamine, respectively gave the amides of Table 4.
    Figure imgb0018
  • Example 20: 3-(3-Acetoxypropyl)-5-(4-chlorophenyl)-­1-phenylpyrazole (7).
  • Compound 1 (1.00 g, 3.20 mM), acetic anhydride (1.0 ml, 11 mM), pyridine (1.0 ml, 12 mM) and CH₂Cl₂ (30 ml) were admixed and the admixture so formed was stirred overnight at room temperature, poured into H₂O (150 ml) and extracted with CH₂Cl₂ (25 ml). The extracts were dried (Na₂SO₄), filtered and concentrated to an oil (1.1 g). Chromatography (silica gel 60; 70 - 230 mesh, 150 g) and elution with Et₂O afforded 1.10 g (94%) of 7 as a colorless oil.
        NMR (CDCl₃) 2.05 (s, 3H, CH₃CO), 1.8 - 2.4 (m, 2H, -CH₂CH₂CH₂), 2.8 (dist t, J ≃ 8Hz, CH₂-), 4.2 (t, 2H, J = 6, Ch₂O), 6.32 (s, 1H, C₄-H), 7.1 - 7.5 (m, 9H, aromatic);
    IR (neat) 2960, 1740, 1600; MS, m/e 354 (M⁺), 311, 281, 268 (100%).
    Anal. Calcd. for C₂₀H₁₉ClN₂O₂:C,67.69;H,5.40;N,7.89
          Found:C,67.78;H,5.36;N,8.07.
  • Example 21: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propyl methyl ether (24).
  • To a suspension of NaH (0.135 g of 60% oil suspension, 3.37 mM) in THF (10 ml) at +5°C was added a solution of 2 (1.05 g, 3.06 mM) in THF (20 ml). After stirring for 30 minutes, methyl iodide (MeI) (0.21 ml, 3.37 mM) was added and the reaction mixture was left to stir overnight. After quenching with CH₃OH, the reaction mixture was concentrated in vacuo, the residue was taken up in EtOAc, washed with H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography (40g, Baker silica gel) with Et₂O as eluent afforded 24 (0.98 g, 90%) as a clear yellow oil.
        NMR (CDCl₃) 1.8 - 2.4 (m, 2H,
    -CH₂CH₂CH₂OCH₃), 2.6 - 3.0 (m, 2H,
    -CH₂CH₂CH₂OCH₃), 3.35 (s, 3H, -CH₂OCH₃), 3.48 (t, J = 7Hz, 2H, -CH₂CH₂OCH₃), 3.78 (s, 3H, aromatic -OCH₃), 6.28 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat) 1250, 830; MS, m/e 357 (M+1, 100%), 323 298.
    Anal. Calcd. for C₂₀H₂₁ClN₂O₂:C,67.31;H,5.93;N,7.85
          Found:C,67.15;H,6.07;N,7.77.
  • Example 22: 5-(4-Chlorophenyl)-3-(3-hydroxybutyl)-­1-(4-methoxyphenyl) pyrazole (20).
  • To a solution of methyl magnesium bromide (MeMgBr) (2.20 ml, 7.04 mM) in Et₂O (15 ml) at 0°C was added a solution of the aldehyde 11 (1.60 g, 4.69 mM) in Et₂O (70 ml) dropwise over a 30 minute period. After stirring for 1 hour the reaction was quenched with a saturated, aqueous NH₄Cl solution. The reaction mixture was partitioned between EtOAc and H₂O. The EtOAc solution was dried (MgSO₄), filtered, and concentrated in vacuo. Chromatography (65g, Baker 40 gm silica gel) of their residue with Et₂O as eluent afforded 20 (1.33 g, 79%) as a clear light yellow oil.
        NMR (CDCl₃) 1.25 (d, J = 6Hz, 3H, -CH(OH)-CH₃) 1.6 - 2.2 (m, 2H, -CH₂ -CH(OH)-), 2.2 -­2.8 (m, 1H, -OH), 2.83 (t, J = 7Hz, 2H, CH₂), 3.78 (s, 3H, -OCH₃), 3.7 - 4.2 (m, 1H, -CH₂-CH(OH)-CH₃), 6.27 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (neat) 3380; MS, m/e 356 (M⁺), 341, 312, 311, 298 (100%). Anal. Calcd. for C₂₀H₂₁ClN₂O₂:C,67.31;H,5.93;N,7.85
          Found:C,67.38;H,6.35;N,7.61.
  • Example 23: 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-(3-oxobutyl)pyrazole (23).
  • To a suspension of pyridinium chlorochromate (3.65 g, 16.93 mM) in CH₂Cl₂ (20 ml) was added the alcohol 20, (3.02 g, 8.46 mM) in CH₂Cl₂ (15 ml). After stirring for 4 hours, the reaction solution was decanted from the chromium precipitates that were washed with EtOAc (2 × 150 ml). The reaction solution and the washes were combined, filtered through florosil, and concentrated in vacuo. Chromatography (120g, Baker 40 gm silica gel) with Et₂O:hexane (1:1 to 100% Et₂O) as eluent, followed by crystallization from Et₂O:hexane afforded 23,2.09 g, 70%) as a white crystalline solid, mp = 85 - 86°C.
        NMR (CDCl₃) 2.20 (s, 3H, -CO-CH₃), 2.7 - 3.2 (m, 4H, -CH₂CH₂-), 3.78 (s, 3H -OCH₃), 6.25 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatic); IR (KBr) 1715; MS, m/e 355 (M+1), 321, 311.
    Anal. Calcd. for C₂₀H₁₉ClN₂O₂:C,67.70;H,5.40;N,7.90
          Found:C,67.41;H,5.24;N,7.90.
  • Example 24: 5-(4-Chlorophenyl)-3-(3-hydroxy-3-methylbutyl)-­1-(4-methoxyphenyl) pyrazole (27).
  • To a solution of MeMgBr (1.32 ml of 3.2 M, 4.23 mM) in THF (15 ml) at 0°C , was added a solution of the ketone 23, (1.00 g, 2.82 mM) in THF (25 ml) dropwise over a 20 minute period. After stirring for 1 hour, the reaction mixture was quenched with a saturated NH₄Cl solution, diluted to a 100 ml volume with Et₂O, washed with H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Chromatography of the residue (Baker silica gel, 45 g) with Et₂O as eluent, afforded 27, (0.68 g, 80% corrected for recovered starting material) as a colorless oil.
        NMR (CDCl₃) 1.30 (s, 6H, -C(CH₃)₂OH), 1.7 - ­2.2 (m, 2H, CH₂C-OH), 2.2 - 2.7 (broad s, 1H, -OH), 2.7 - 3.1 (m, 2H, CH₂), 3.78 (s, 3H, -OCH₃), 6.25 (s, 1H, C₄-H), 6.6 - 7.4 (m, 8H, aromatic); IR (neat) 3390, 1250; MS (20 eV EI), m/e 370 (M⁺), 355, 312 (100%), 311, 298.
    Anal. Calcd. for C₂₁H₂₃ClN₂O₂:C,68.01;H,6.25;N,7.55
          Found:C,67.80;H,67.80;H,6.30;N,7.24.
  • Example 25: 5-(4-Chlorophenyl)-3-(3-oximinopropyl)-­1-(4-methoxyphenyl) pyrazole (26).
  • To a solution of the aldehyde 11 (1.00 g, 2.93 mM) in EtOH (30 ml) was added hydroxylamine hydrochloride (0.31 g, 4.40 mM) and pyridine 0(.47 g, 5.87 mM). After stirring overnight at room temperature, the reaction mixture was concentrated in vacuo. The remaining residue was taken up in CH₂Cl₂, washed H₂O, dried (Na₂SO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O:hexane afforded 26, (0.67 g, 64%) as a white crystalline solid, mp = 134 - 135°C.
        NMR (CDCl₃) 2.5 - 3.3 (m, 5H, -CH₂CH₂- and =N-OH), 3.78 (s, 3H, -OCH₃), 6.30 (s, 1H, C₄-H), 6.5 - ­7.4 (m, 9H, aromatic and -CH₂-CH=N-OH); IR (KBr) 3210; MS (20 eV EI), m/e 355 (M⁺), 338 (100%), 311, 297.
    Anal. Calcd. for C₁₉H₁₈ClN₃O₂:C,64.13;H,5.10;N,11.81
          Found:C,63.79;H,4.93;N,11.53.
  • Example 26: 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-[3(Z)-hexadecenyl] pyrazole (33).
  • To a solution of hexamethyldisilazane (0.70 ml, 3.34 mM) in THF (30 ml) at +5°C was added 1.55M n-BuLi (1.97 ml, 3.05 mM). The cooling bath was removed and after 15 minutes tridecyltriphenyl phosphonium bromide (1.68 g, 3.20 mM) was added. After stirring for 0.5 hour, the aldehyde 11 (0.99g, 2.90 mM) was added, the reaction mixture was stirred for an additional 30 minutes, and concentrated in vacuo. The residue was taken up in Et₂O:hexane (1:1), filtered, and concentrated in vacuo to afford crude 33 (1.42 g). Chromatography (Baker silica gel, 55 g) with Et₂O:hexane (1:2) as eluent afforded 33, (0.95 g, 65%) as a clear colorless oil.
        NMR (CDCl₃) 0.7 - 3.1 (m, 29H,
    -CH₂CH₂CHCH(CH₂)₁₁CH₃), (3.80 (s, 3H, -OCH₃),
    5.3 - 5.7 (m,2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.6 - ­7.5 (m, 8H, aromatic); IR (neat) 2940, 2860; MS (20 eV EI), 508 (M+2), 506 (M⁺), 449, 351, 338, 298 (100%).
    Anal. Calcd. for C₃₂H₄₃ClN₂O:C,75.78;H,8.55;N,5.52
          Found:C,75.54;H,9.03;N,5.44.
  • Example 27: 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-[4-phenyl-3(E)-butenyl] pyrazole (14); and 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-[4-phenyl-3(E,Z)-butenyl] pyrazole (15).
  • To a suspension of pyridinium chlorochromate (6.29 g, 29.2 mM) in CH₂Cl₂ (40 ml) was added the alcohol 2, (5.00 g, 14.6 mM) in CH₂Cl₂ (30 ml). After stirring for 4 hours, the reaction solution was decanted from the chromium residue on the sides of the reaction vessel. This residue was washed with EtOAc (2 × 200 ml), and the washes were combined with the reaction solution, filtered through florisil, and concentrated in vacuo. Crystallization from Et₂O afforded the crude aldehyde 11 (4.20 g, 84%) contaminated with the dimer ester 16.
  • To a solution of hexamethyldisilazane (1.07 ml, 5.06 mM) in dry THF (50 ml) at +10°C was added n-BuLi (2.98 ml, 4.62 mM). The cooling bath was removed, and after 15 minutes benzyltriphenyl phosphonium chloride (1.88 g, 4.84 mM) was added. After 45 minutes the crude aldehyde 11 (1.50 g, 4.40 mM) in THF (10 ml) was added, the reaction mixture was stirred for an additional 30 minutes and concentrated in vacuo. The residue was taken up into Et₂O (150 ml), filtered, and concentrated in vacuo.
        Chromatography of this residue (Baker silica gel, 85 g) with Et₂O:hexane (1:1 to 100% Et₂O) afforded the E olefin 14, the E/Z olefins 15, and dimer ester 16. Compound 14 was crystallized from Et₂O:hexane. All products were combined with those of an equivalent run using the same procedure on a 2.93 mM scale of the aldehyde 11. This afforded the E olefin 14, (1.33 g, 44%) as a white crystalline solid, mp = 93 - 95°C, the mixed E/Z olefin 15, 7:3 Z:E (1.12 g, 37%) as a clear colorless oil; and dimer ester 16 (0.40 g, 8.0%).
  • Compound 14 NMR (CDCl₃) 2.4 - 3.2 (m, 4H, -CH₂çH₂-), 3.80 (s, 3H, OCH₃), 6.2 - 6.7 (m, 2H, CH=CH), 6.30 (s, 1H, C₄-H), 6.7 - 7.6 (m, 13H, aromatic); IR (KBr) 1245; MS, m/e 414 (M⁺), 310, 297 (100%).
    Anal. Calcd. for C₂₆H₂₃ClN₂O:C,75.26;H,5.59;N,6.75
          Found:C,75.45;H,5.77;N,6.77.
  • Compound 15, NMR (CDCl₃) 2.5 - 3.2 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, COH₃), 5.5 - 6.7 (m, 2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.7 - 7.6 (m, 13H, aromatic); IR (neat) 1250; MS, m/e 414 (M⁺), 311, 297, (100%).
    Anal .Calcd. for C₂₆H₂₃ClN₂O:C,75.26;H,5.59;N6.75
          Found:C,74.86;H,5.96;N,6.61.
  • Example 28: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl] propyl 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl] propionate (16)
  • To a solution of the carboxylic acid 12 (0.40 g, 1.12 mM) in THF (10 ml) at 0°C, was added one drop of DMF and oxalyl chloride (0.12 ml, 1.35 mM). After stirring for 15 minutes the cooling bath was removed and stirring was continued for 1 hour The reaction mixture was concentrated in vacuo (to remove the excess oxalyl chloride), taken up in THF (10 ml), and cooled to 0°C. To this solution was added the alcohol 2 (0.38 ml, 1.12 mM) and Et₃N (0.47 ml, 3.36 mM). After 15 minutes the cooling bath was removed and stirring was continued for 1 hour. The reaction mixture was diluted to 50 ml with Et₂O, washed with H₂O, dried (MgSO₄), filtered and concentrated in vacuo Chromatography (Baker silica gel, 45 g) with Et₂O:hexane (9:1) as eluent, afforded 16 (59%) as a white semi-solid.
        NMR (CDCl₃) 1.8 - 2.4 (m, 2H, -CH₂CH₂CH₂-), 2.5 - 3.3 (m, 6H,
    -CH₂-CH₂CH₂OCOCH₂-CH₂-), 3.80 (s, 6H, 2-OCH₃),
    4.25 (t, J = 6.5Hz, 2H, -CH₂CH₂OCO-), 6.27 + 6.33 (2s, 2H, 2× C₄-H), 6.7 - 7.5 (m, 16H, aromatic); IR (KBr) 1730; MS (DCI), 681 (M+1), 325.
    Anal. Calcd. for C₃₈H₃₄Cl₂N₄O₄:C,66.96;H,5.03;N,8.22
          Found:C,66.60;H,4.90;N,7.83.
  • Example 29: 3-[4-(4-Carbomethoxyphenyl)-3(E)-­butenyl]-5-(4-chlorophenyl)-­1-(4-methoxyphenyl) pyrazole (25).
  • To a solution of hexamethyldisilazane (1.08 ml, 5.13 mM) in THF (50 ml) at +5°C was added n-BuLi (3.02 ml of 1.55 M, 4.68 mM). After 15 minutes
    (4-carbomethoxyphenyl)triphenyl phosphonium chloride (2.19 g, 4.91 mM) was added, and the cooling bath was removed. After 30 minutes the aldehyde 11 (1.52 g, 4.46 mM) in THF (10 ml) was added, and the reaction mixture was stirred for an additional 0.5 hour. Concentration in vacuo of the reaction mixture and chromatography (Baker silica gel, 80 g) with Et₂O:hexane (1:1 to 100% Et₂O) as eluent afforded 25. Recrystallization from Et₂O afforded pure 25 (1.10 g, 48%) as a white crystalline solid, mp = 126 - ­128°C.
        NMR (CDCl₃) 2.5 - 3.1 (m, 4H, -CH₂CH₂-), 3.80 (s, 3H, -OCH₃), 3.90 (s, 3H, -COOCH₃), 5.8 - 6.7 (m, 2H, -CH=CH-), 6.30 (s, 1H, C₄-H), 6.7 - 8.2 (m, 12H, aromatic); IR (KBr) 1725; MS, m/e 472 (M⁺), 441, 297 100%).
    Anal. Calcd. for C₂₈H₂₅ClN₂O₃:C,71.10;H,5.33;N,5.92
          Found:C,71.30;H,5.22;N,5.97.
  • Example 30: Methyl 3-[5-(4-chlorophenyl)-1-(4-­methoxyphenyl)-3-pyrazolyl] propionate (19).
  • To a solution of the acid 12 (0.98 g, 2.75 mM) in Et₂O (10 ml) and CH₂Cl₂ (15 ml) at 0°C, was added a CH₂N₂ solution in Et₂O (prepared from N-nitroso-N-methylurea, 40% KOH/Et₂O) until a persistent yellow color was observed in the reaction mixture. The reaction mixture was dried (MgSO₄), filtered and concentrated in vacuo. Crystallization from EtOAc:hexane afforded 19 (0.85 g, 83%) as a white crystalline solid, mp = 117 - 118°C.
        NMR (CDCl₃) 2.5 - 3.4 (m, 4H, -CH₂CH₂-), 3.70 (s, 3H, -COOCH₃), 3.80 (s, 3H, -OCH₃), 6.28 (s, 1H, C₄-H), 6.7 - 7.4 (m, 8H, aromatics); IR (KBr) 1730; MS, m/e 370 (M⁺), 339, 311 (100%).
    Anal. Calcd. for C₂₀H₁₉ClN₂O₃:C,64.77;H,5.16;N,7.56
          Found:C,64.47;H,5.15;N,7.65.
  • Example 31: 3-(3-Acetoacetoxypropyl)-5-(4-chlorophenyl)-­1-(4-methoxyphenyl)pyrazole (59).
  • 5-(4-Chlorophenyl)-3-(3-hydroxypropyl)-1-­(4-methoxyphenyl) pyrazole (1.71 g, 0.005 moles) and 2,2,6-trimethyl-1,3-dioxen-4-one (0.71 g, 0.005 moles) were disolved in 100 ml of xylenes. The solution was stirred under reflux for 16 hours. At the time, the solution was cooled to room temperature, and concentrated in vacuo to a yellow oil. The oil was flash chromatographed on silica gel to afford 59 (1.7 g, 80%) as a pale yellow oil.
        NMR (CDCl₃) 1.8 - 2.4 (m, 2H, CH₂CH₂CH₂), 2.1 (s, 3H, COCH₃), 2.8 (t, 2H, J = 7Hz, CH₂), 3.48 (s, 2H, COCH₂CO), 3.85 (s, 3H, OCH₃), 4.25 (t, 2H, J = 7Hz, CH₂OCO), 6.25 (s, 1H, C₄-H), 6.9 (d, J = 8Hz, 2 aromatic H), 7.0 - 7.4 (m, 6H, aromatic H); IR (neat) 1750, 1725; MS, m/e 426 (M⁺), 341.
    Anal. Calcd. for C₂₃H₂₃ClN₂O₄:C,64.71;H,5.43;N,6.56
          Found:C,64.97;H,5.67;N,6.13.
  • Example 32: 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]propylamine (96).
  • To a suspension of LiAlH₄ (0.13 g, 3.5 mM) in THF (15 mL) was added a solution of the amide 31, (1.00 g, 2.81 mM) in THF (15 ml), dropwise, keeping the reaction temperature below reflux. The reaction mixture was heated to reflux, and refluxed for 17 hours, when it was quenched with 0.13 ml H₂O, 0.13 mL 20% NaOH solution and an additional 0.39 ml H₂O. The reaction mixture was filtered and concentrated in vacuo. The remaining residue was taken up into EtOAc (50 mL) and extracted with a 1.0 N HCl solution (2×25 mL). The aqueous extracts were combined and washed with EtOAc (25 mL), neutralized with a 2N NaOH solution, and extracted with EtOAc (2×50 mL). The organic extracts were dried (Na₂SO₄), filtered and concentrated in vacuo to afford the title compound (0.86 g, 90%) as a light yellow oil.
        NMR (CDCl₃) 1.6-2.3 (m, 4H, -CH₂CH₂CH₂NH₂), 2.6-3.1 (m, 4H, -CH₂CH₂CH₂NH₂), 3.78 (s, 3H, -OCH₃), 6.27 (s, 1H, C₄-H), 6.6-7.5 (m, 8H, aromatic); IR (neat) 3380, 1520; MS (DCI), m/e 344( MH⁺ +2), 342 (MH⁺, 100%).
    Anal. Calcd. for C₁₉H₂₀ClN₃O:C,66.76;H,5.90;N,12.29.
          Found:C,66.70;H,5.97;N,11.83.
  • Example 33: 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]propanenitrile (95).
  • To a suspension of compound 31, (7.75 g, 21.8 mM) in dry benzene (400 mL) was added SOCl₂ (4.78 mL, 65mM). The reaction mixture was heated to reflux for three days and then cooled at 0°C. Any excess SOCl₂ was decomposed with ice water. 50 mL of H₂O was added to the reaction mixture which was then neutralized with 50% NaOH, washed with H₂O (2×50mL), dried (Na₂SO₄), filtered, and concentrated in vacuo. Crystallization from Et₂O, Hexane afforded the title compound (6.43 g, 87%) as a light yellow crystalline solid, mp = 107-109°C.
        NMR (CDCl₃) 2.4=3.2 (m, 4H, -CH₂CH₂-), 3.82 (s, 3H, OCH₃), 6.41 (s, 1H, C₄-H), 6.7-7.5 (m, 8H, aromatic); IR (KBr) 2250, 1510; MS(EI) m/e 339 (M+2, lCl), 337 (M⁺, 100%).
    Anal. Calcd. for C₁₉H₁₆ClN₃O:C,67.55;H,4.77;N,12.44
          Found:C,67.23;H,4.88;N,12.21
  • Example 34 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-met hyl-N-succinyloxy- propanamide.
  • To a solution of the hydroxamic acid 3 (5.0 g, 12.96 mM) in dry pyridine (13 ml) was added succinic anhydride (1.3 g, 12.99 mM) in pyridine (5 ml) and the resulting solution was stirred for 72 hours. The pyridine was removed in vacuo and the residue was triturated with hexane and recrystallized from Et₂O to afford pure 34 (6.21 g, 98%) as a white solid, mp = 146-147°. MS, m/e 485(M⁺).
    Anal. Calcd. for C₂₄H₂₄ClN₃O₆: C,59.32; H,4.98; N,8.65
          Found: C,59.68; H,4.97; N,8.75
  • Employing a similar procedure, the compounds of Table 5 were synthesized.
    Figure imgb0019
  • Example 35 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-­Nʹ,Nʹ-dimethylglycinyloxy-N-methylpropanamide (134)
  • Compound 3 (6.0 g, 15.55 mM) was added to a suspension of N,N-dimethyl-glycine (1.61 g, 15.61 mM) and NʹNʹ-dicyclohexylcarbodiimide (3.21 g, 15.55mM) in dry pyridine (22 ml) under nitrogen and stirred for 44 hours. The solvent was removed in vacuo and the residue triturated with CH₂Cl₂, filtered, and the filtrate evaporated to dryness. Recrystallization from CH₂Cl₂/Et₂O afforded pure 35 (6.8 g, 93%) as a white solid, mp = 103-104°, MS, m/e 470 (M⁺).
    Anal. Calcd. for C₂₄H₂₇C1N₄O₄: C,61.20; H,5.78; N,11.90
          Found: C,61.26; H,5.94; N,11.79
  • The oxalate salt of 35 was synthesized as the trihydrate as a white solid, mp = 114-115°. Anal. Calcd. for C₂₄H₂₇ClN₄O₄·C₂H₂O₄·3H₂O:C,50.77;H,5.74;N,9.11
          Found:C,50.68;H,5.73;N,8.64
  • In a similar manner, the compounds of Table 6 were synthesized.
    Figure imgb0020
  • Example 36 3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]­N-chloroacetyloxy-N-methylpropanamide (139)
  • To a solution of 3 (7.0 g, 18.14 mM) in anhydrous THF (125 ml) was added methylmorpholine (1.99 ml, 18.1 mM) and the resulting solution was cooled to -10° C under nitrogen. Chloroacetyl chloride (1.44 ml, 18.1 mM) was added and stirred for 10 minutes, filtered and the filtrate concentrated in vacuo. The residue was recrystallized from Et₂O to afford pure 36 (5.7 g, 68%) as a white solid, mp = 110-111°. MS, m/e 461 (M⁺).
    Anal. Calcd. for C₂₂H₂₁Cl₂N₃O₄: C,57.15; H,4.58; N,9.09
          Found: C,57.42; H,4.55; N,8.99.
  • Employing a similar procedure to that of Example 36, the compounds of Table 7 were synthesized.
    Figure imgb0021
  • Following the procedure of Example 5, but using the appropriate hydroxylamine gave the compounds of Table 8.
    Figure imgb0022
  • Example 37 3-[4-Bromo-5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]-propionic acid (147)
  • The acid 12 (3.57 g, 10 mM) and N-bromosuccinimide (1.78 g, 10 mM) were dissolved in a mixture of CCl₄ (150 ml) and CHCl₃ (20 ml) and allowed to stir for 16 hours. The solvents were evaporated in vacuo and the residue was dissolved in CHCl₃, washed with H₂O, dried (Na₂SO₄), filtered and evaporated to give an oil which was crystallized from Et₂O to afford pure 37 (2.18 g, 50%) as a white solid, mp = 147.5-148°. MS ,m/e 435 (MH⁺).
    Anal. Calcd. forC₁₉H₁₆BrClN₂O₃: C,52.37; H,3.70; N,6.43
          Found: C,52.58; H,3.69; N,6.27.
  • Substitution of N-chlorosuccinimide for N-bromosuccinimide gave the corresponding 4-chloro derivative as a white solid, mp = 123.5-124.5°. MS, m/e 391(MH⁺) (Compound Number 182)
    Anal. Calcd. for C₁₉H₁₆Cl₂N₂O₃·1/4H₂0: C,57.66; H,4.20; N,7.08
          Found: C,57.78; H,4.12; N,6.96.
  • Using the acids synthesized in Example 37 and following the procedure described in Example 5 gave the compounds of Table 9.
    Figure imgb0023
  • Substituting Compound 2 for the acid 12 in Example 37 afforded 4-bromo-5-(4-chlorophenyl)-3-(3-­hydroxypropyl)-1-(4-methoxyphenyl)pyrazole, as an off-white solid, 87%, mp = 118.5-120°. MS, m/e 420 (M⁺) (Compound Number 183).
    Anal. Calcd. for C₁₉H₁₈BrClN₂O₂: C, 54.11; H, 4.30; N. 6.64
          Found: C, 54.20; H, 4.35; N. 6.59
  • Following a similar procedure, but employing N-chlorocuccinimide gave 4-chloro-5-(4-chlorophenyl)-3-(3-­hydroxypropyl)-1-(4-methoxyphenyl)pyrazole as a tan solid; mp = 113-115°. MS, m/e 376 (M⁺) (Compound Number 184). Anal. Cald. for C₁₉H₁₈Cl₂N₂O₂: C, 60.49; H, 4.81; N, 7.43
          Found: C, 60.30; H, 4.82; N, 7.36
  • Example 38 N-[3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-­propyl]hydroxyl-amine (151)
  • To a solution of the oxime 26 (2.70 g, 7.59 mM) in MeOH (50 ml), containing methyl orange (2 mg) as as indicator, was added a solution of NaBH₃CN (0.52 g, 8.4 mM) in MeOH (20 ml), and a solution of 2N HCl, simultaneously, at such a rate to maintain a pH of 3 to 4. The reaction was stirred for 3 hours at room temperature, acidified to pH 1 and concentrated in vacuo. The residue was diluted with H₂O (100 ml), adjusted to pH 8.5 with 5N NaOH, and extracted with EtOAc. The extracts were combined, dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was chromatographed on Merck Silica Gel 60 (90 g, 230-400 mesh) with EtOAc:MeOH (9:1) as eluent. Crystallization from Et₂O afforded pure 38 (1.64 g, 60%) as a white solid, mp = 91-93°. MS, m/e 357 (M⁺).
    Anal. Calcd. for C₁₉H₂₀ClN₃O₂: C,63.77; H,5.63; N,11.74
          Found: C,63.63; H,5.74; N,11.63.
  • Example 39 N-[3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-­propyl]-N-hydroxy-acetamide (152)
  • To a solution of hydroxylamine 38 (1.25 g, 3.49 mM) and Et₃N (0.97 ml, 6.9mM) in THF (35 ml) was added acetyl chloride (0.25 ml, 3.5 mM) and the reaction mixture stirred for 1 hour, diluted with EtOAc (165 ml), washed with H₂O, dried (Na₂SO₄), filtered and concentrated in vacuo to give a residue which was recrystallized from EtOAc:Et₂O to afford pure 39 (1.06 g, 76%) as a white crystalline solid, mp = 121-123°. MS, m/e 399 (M⁺).
    Anal. Calcd. for C₂₁H₂₂ClN₃O₃: C,63.07; H,5.55; N,10.51
          Found: C,62.83; H,5.95; N,10.43.
  • Following a similar procedure to that of Example 39 and employing the appropriate acyl chloride afforded the compounds of Table 10.
    Figure imgb0024
  • Example 40 Ethyl N-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]-propyl]- hydroxyoxamate (157)
  • Following a similar procedure to that of Example 39, but employing ethyl oxalyl chloride in place of acetyl chloride afforded 40 as a white foam; MS, m/e 457 (M⁺).
    Anal. Calcd. for C₂₃H₂₄ClN₃O₃: C,60.33; H,5.28; N,9.18
          Found: C,60.55; H,5.67; N,9.18.
  • Example 41 N-[3-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-­propyl]-N,Nʹ-dihydroxyoxamide (158)
  • To a solution of hydroxylamine.HCl (0.25 g, 3.5 mM) and the ester 7C (0.81 g, 1.8mM) in EtOH (17 ml) was added in 1N NaOEt solution (7.1 ml, 7.1 mM). After stirring for 2.5 hours the reaction mixture was acidified and concentrated in vacuo. The residue was diluted with CHCl₃, washed (H₂O), dried (Na₂SO₄), filtered and concentrated in vacuo. Crystallization from EtOAc:Et₂O afforded pure 41 as a white crystalline solid, mp = 145-146.5° MS, m/e 444 (M⁺).
    Anal. Calcd. for C₂₁H₂₁ClN₄O₅·0.25 H₂O: C,56.13;H,4.82;N,12.47
          Found: C,56.16;H,4.76;N,12.32.
  • Example 42 2-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-ethyl amine (159)
  • To a solution of the acid 12 (1.0 g, 2.8 mM) in benzene (25 ml) was added Et₃N (0.39 ml, 2.8 mM) and diphenylphosphoryl azide (0.60 ml, 2.8 mM). After stirring overnight at room temperature, the reaction mixture was heated to 70°C for 1.5 hours, cooled and concentrated in vacuo.. Dioxane (2 ml), followed by a solution of concentrated HCl (0.3 ml) in dioxane (2 ml) was added, and the reaction mixture was heated to reflux for 2 hours, cooled and diluted to 50 ml with EtOAc. The organic solution was washed with 0.25N NaOH solution, and extracted with 1N HCl. The extracts were combined, basified with 5N NaOH, and extracted with EtOAc, dried, filtered and concentrated in vacuo. Crystallization from Et₂O afforded pure 42 (0.62 g, 68%) as a light yellow crystalline solid, mp= 95-97°. MS, m/e 327 (M⁺).
    Anal. Calcd. for C₁₈H₁₈ClN₃O: C, 65.95; H,5.53; N,12.82
          Found: C, 66.14; H,5.57; N,13.10.
  • Example 43 Ethyl 2-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]-ethylamine-N-oxoacetate (160)
  • To a solution of the amine 42 (3.24 g, 9.8 mM) and Et₃N (1.56 ml, 10.9 mM) in THF (100 ml) was added ethyloxalyl chloride (1.1 ml, 9.8 mM). After stirring overnight the reaction mixture was diluted to 400 ml with EtOAc, washed with H₂O,dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was chromatographed on Merck Silica Gel 60 (110 g, 230-400 mesh) with EtOAc:Hexane (3:1) as eluent. Crystallization from EtOAc:Hexane afforded pure 43 (3.6 g, 85%) as a white crystalline solid, mp = 93-94°. MS, m/e 427 (M⁺).
    Anal Calcd. for C₂₂H₂₂ClN₃O₄: C,61.75; H,5.18; N,9.82
          Found: C,61.56; H,5.29; N,9.78
  • Example 44 Ethyl 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3- pyrazolyl]-propylamine-N-oxoacetate (161)
  • Following the procedure of Example 43, but substituting the amine 96of Example 32 for the amine 42 afforded 44 as a yellow oil; MS, m/e 441 (M⁺).
    Anal. Calcd. for C₂₃H₂₄ClN₃O₄: C,62.51; H, 5.49; N,9.51
          Found: C, 62.41; H,5.66; N,9.35.
  • The compounds of Table 11 were synthesized from compounds 43 or 44 by standard methods..
    Figure imgb0025
  • Example 45 N-Acetyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]-propyl-amine (167)
  • To a solution of the amine 96 (0.96 g, 2.8 mM) and Et₃N (0.59 ml, 4.2 mM) in THF (25 ml) was added acetyl chloride (0.2 ml, 2.8 mM). After stirring for 1 hour the reaction mixture was diluted to 200 ml with EtOAc, washed with H₂O, dried, filtered and concentrated in vacuo. Crystallization from EtOAc:Et₂O afforded pure 45 (0.78 g, 72%) as an off-white crystalline solid, mp = 129-131°. MS, m/e 383 (M⁺).
    Anal. Calcd. for C₂₁H₂₂ClN₃O₂: C,65.70; H,5.78; N,10.95
          Found: C,65.85; H,6.00; N,10.88.
  • Following the procedure of Example 45, but substituting trimethylacetyl chloride, methanesulfonyl chloride and diethyl chlorophosphate respectively for acetyl chloride gave the compounds of Table 12.
    Figure imgb0026
  • Example 46 N-Acetyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]-N-hydroxy-propanamide (171)
  • A white slurry of compound 29 of Example 12 (5.0 g, 13.45mM) in CH₂Cl₂ (200 ml) and Et₃N (1.88 ml, 13.48 mM) was cooled to -10°C under nitrogen, and treated with acetyl chloride (0.91 ml, 12.8 mM). The mixture was allowed to stir at -10°C for 45 minutes, filtered and the filtrate concentrated in vacuo to give crude product which was purified via flash column chromatography (EtOAc) and recrystallized from Et₂O to afford 46 as a white solid, mp = 110-111°. MS, m/e 413 (M⁺).
    Anal. Calcd. for C₂₁H₂₀ClN₃O₄: C,60.94; H,4.87; N,10.15
          Found: C,61.19; H,5.15; N, 9.77.
  • Example 47 N-Acetyl-N-acetoxy-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-­3-pyrazolyl]-propanamide (172)
  • Following the procedure of Example 46, but employing 2 equivalents of acetyl chloride afforded 47 as a white solid, mp = 111-112°. MS, m/e 455 (M⁺). Anal. Calcd. for C₂₃H₂₂ClN₃O₅: C,60.59; H,4.86; N,9.22
          Found: C,60.52; H,5.12; N,9.06.
  • Example 48 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-(3-oxobutyl)-­pyrazole thiazol-2-yl hydrazone (173)
  • A solution of compound 23 (2.15 g, 6.06 mM) in EtOH (6.2 ml) and glacialacetic acid (0.2 ml) was warmed to 35° and 2-thiazolylhydrazine (0.698 g, 6.06 mM) was added. Stirring was continued for 80 minutes and the resulting brown solution was cooled to room temperature for 1 hour, then allowed to stand at -15°, filtered, and recrystallized from EtOH to afford 48 as a tan solid (1.22 g, 45%), mp = 128-129°. MS, m/e 451 (M⁺).
    Anal. Calcd. for C₂₃H₂₂ClN₅S: C,61.12; H,4.91; N,15.50
          Found: C,60.89; H,4.81; N,15.12.
  • Following the procedure of Example 48, but substituting the appropriate ketone from Table 15 or aldehyde 11 for compound 23 afforded the compounds of Table 13.
    Figure imgb0027
  • Following the procedure of Example 22, but substituting ethyl magnesium bromide, phenyl magnesium bromide and t-butyl magnesium chloride for methyl magnesium bromide gave the compounds of Table 14.
    Figure imgb0028
  • Following the procedure of Example 23, but substituting the appropriate alcohol from Table 14 for compound 20 afforded the compounds of Table 15.
    Figure imgb0029
  • Example 49 2-[5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-ethyl carboxamidoxime (184)
  • To a suspension of nitrile 95 (1.0 g, 2.96 mM) in MeOH (6 ml) was added NaHCO₃ (0.50 g, 5.9 mM) and a solution of hydroxylamine.HCl (0.40 g, 5.9mM) in H₂O (5 ml). The reaction was heated to reflux for 16 hours, concentrated in vacuo and the residue partitioned between H₂O and CHCl₃. The CHCl₃ layer was dried (Na₂SO₄), filtered and concentrated in vacuo to a white foam. Crystallization from EtOAc afforded pure 49 (0.65 g, 59%) as a white crystalline solid, mp = 132-134°. MS, m/e 370 (M⁺).
    Anal. Calcd. for C₁₉H₁₉ClN₄O₂·0.25 H₂0: C,60.80;H,5.24;N,14.93
          Found: C,60.73;H,5.18;N,14.74.
  • Example 50 N-Hydroxy-N-methyl-2-[5-(4-chlorophenyl)-1-(4-methoxyphenyl) -3-pyrazolyl] ethylcarboximidamide Monohydrate (185)
  • Following the procedure of Example of 48, but substituting N-methylhydroxylamine.HCl for hydroxylamine.HCl afforded 50 as a white solid, mp = 106-110°. MS, m/e 384 (M⁺).
    Anal. Calcd. for C₂₀H₂₁N₄O₂·H₂O: C,59.62;H,5.75;N,13.91
          Found: C,59.62;H,5.65;N,13.61.
  • Following the procedure of Example 18, but substituting octylamine for diethylamine gave the following compound.
    Figure imgb0030
  • Example 51 3-[1-(4-Methoxyphenyl)-5-(4-methylphenyl)-4-methyl-3-­pyrazolyl]-N-hydroxy-N-methylpropanamide (187) 5-Methyl-6-(4-methylphenyl)-4,6-dioxohexanoic acid
  • Following the procedure employed for the synthesis of the 4,6-dioxohexanoic acids of Table 2ʺ-AP, but substituting 4ʹ-methylpropiophenone for the appropriately substituted acetophenone gave the title compound 5-methyl-6-(4-methylphenyl)-4,6-dioxohexanoic acid.
  • 3-[1-(4-Methoxyphenyl)-5-(4-methylphenyl)-4-methyl-3-­pyrazolyl]propionic acid
  • Following the procedure employed for the synthesis of the pyrazole propionic acids of Table 2ʺ, but substituting compound 5-methyl-6-(4-methylphenyl)-4,6-­dioxohexanoic acid for the appropriate 6-aryl-4,6-­diketohexanoic acid gave 3-[1-(4-methoxyphenyl)-5-­(4-methylphenyl)-4-methyl-3-pyrazolyl]propionic acid.
  • 3-[1-(4-Methoxyphenyl)-5-(4-methylphenyl)-4-methyl-3-­pyrazolyl]-N-hydroxy-N-methylpropanamide (187)
  • Following the procedure of Example 5, but substituting the propionic acid compound obtained above for the acid 12 gave 3-[1-(4-methoxyphenyl)-5-­(4-methylphenyl)-4-methyl-3-pyrazolyl]-N-hydroxy-N-methyl­propanamide the title compound.
  • IN VIVO ALLEVIATION OF INFLAMMATION
  • Polyarthritis was induced in Lewis strain laboratory rats (weight = about 200 grams) by injection of a suspension of Mycobacterium butyricum in mineral oil into the subplantar tissue of the mammal's hind paws. On day 10 after the injection, the rats were assigned to groups, and paw volumes and body weights were recorded. Paw volumes of the contralateral, uninjected hind paw were determined by mercury plethylsmography. Per oral (p.o.) dosing began and continued for five consecutive days thereafter. On day 14 after the initial injection, approximately four hours after the final dose was administered, paw volumes and body weights were recorded and quantitated.
  • Anti-inflammatory activity of the substituted pyrazole compounds is expressed as the percent inhibition of paw volume increase. The results of this study for several compounds of the structure shown below are shown in Table 16, hereinafter.
    Figure imgb0031
    Figure imgb0032
    Figure imgb0033
    Figure imgb0034
    Figure imgb0035
    Figure imgb0036
  • In addition, the results for compounds of the structure shown below are shown in Table 17.
    Figure imgb0037
  • The present invention has been described with respect to prefered embodiments. It will be clear to those skilled in the art that modifications and/or variations of the disclosed subject matter can be made without departing from the scope of the invention set forth herein.

Claims (15)

1. Compound having a structure that corresponds to the formula:
Figure imgb0038
    wherein
    R₁, R₂, R₃ and R₄ are the same or different and are individually selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkythio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, amino, acetamido, carboxy, alkylhydroxamic acid, or where R₁R₂ or R₃R₄, taken together with the phenyl group to which they are attached, form a naphthyl or substituted naphthyl group;
    R is a straight chained, saturated or unsaturated hydrocarbon that contains 2-16 carbon atoms;
    Y is hydrogen, bromo, chloro or lower alkyl;
    and X is selected from the group consisting of carboxy, hydroxy, acetoxy, alkanoyloxy, lower alkoxy, lower alkyl carbonyl, oximino, cyano, amino, C(O)-R₅ and -C(O)C(O)-R₅ wherein R₅ is selected from the group consisting of hydrogen, alkyl, lower alkoxy, NR₆R₇ wherein R₆ or R₇ are the same or different and are selected from the group consisting of hydrogen and lower alkyl, or R₆ or R₇ are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, hydroxy, acyloxy, benzyloxy, 2-hydroxy lower alkyl, lower alkyl carboxy, phenyl, substituted phenyl, pyridyl, thiazolyl, dihydrothiazolyl, 5-tetrazolyl, -OCO(CH₂)nCOR₉ wherein R₉ is -OH, -ONa, dialkylamino such as diethylamino and morpholino, and n is 2 or 3; -OCOR₁₀ wherein R₁₀ is -CH₂NR₁₁R₁₂ wherein R₁₁ and R₁₂ are alkyl, such as methyl, cycloalkyl such as cyclohexyl, or together are a heterocyclic ring such as N-methylpiperazino, -OCOR₁₀ wherein R₁₀ is -CH₂Cl, -CH₂O-lowerakyl or t-butyl, -CH-loweralkyl-CO₂-Q, wherein Q is lower alkyl or -H, acyl such as acetyl, propionyl or butyryl; -NR₈OH wherein R₈ is hydrogen, -CO-loweralkyl, -CO-t-butyl, -COC₇H₁₅, -CO-phenyl, SO₂-lower alkyl, -COCO₂-lower alkyl, and -COCONHOH; -NHR₁₃ wherein R₁₃ is hydrogen, -CO-lower alkyl, -CO-tbutyl, -COC₇H₁₅, -CO-phenyl, -SO₂-lower alkyl, -COCO₂-lower alkyl, -COCONHOH, -COCO₂H, COCON(lower alkyl)OH, and PO(O-lower alkyl)₂;
-C(R₁₄)=NNH-2-thiazolino, -CH(OH)R₁₄ and -C(O)R₁₄ wherein R₁₄ is hydrogen, lower alkyl, phenyl and tbutyl; -C(=NOH)NH₂ and -C(=NH)N(OH)-lower alkyl, ω-alkanoate and O-NR₈R₉ wherein R₈ and R₉ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, phenyl and substituted phenyl;
    with the provisos that:
(a) when Y is bromo or chloro, X is -COOH, -CH₂OH or -C(O)-R₅ wherein R₅ is NR₆R₇ and R₆ is OH and R₇ is lower lakyl;
(b) at least one of R₁ and R₂ is other than hydrogen where (i) R-X is (CH₂)₂CO₂H or (CH₂)₂C(O)NHOH, and (ii) R₃ and R₄ are 4-methoxy, 3-methoxy-4-hydroxy, 2-hydroxy and hydrogen and
(c) at least one of R₁ and R₂, or of R₃ and R₄ is other than hydrogen where R-X together contains three saturated carbon atoms linked together by carbon-carbon bonds; and pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 wherein R₂ and R₄ are hydrogen, and R₁ and R₃ are selected from the group consisting of halo, trifluoromethyl, lower alkyl and lower alkoxy.
3. The compound according to claim 2 wherein R is straight chained, saturated and contains three carbon atoms bonded together with carbon-carbon bonds.
4. The compound according to claim 3 wherein X is selected from the group consisting of hydroxy, carboxy, a carboxylate salt of a pharmaceutically acceptable cation, C(O)-NR₆R₇ wherein R₆ and R₇ are selected from the group consisting of hydrogen, hydroxyl, methyl, tbutyl, 2-hydroxyethyl and carboxymethyl.
5. The compound according to claim 2 wherein R is unsaturated and contains 2-16 carbon atoms.
6. The compound according to claim 5 wherein X is carboxyl or a salt thereof.
7. A compound of claim 1 selected from the group consisting of N-carboxymethyl-3-[5-(4-chlorophenyl)-­1-(4-methoxyphenyl)-3-pyrazolyl] propanamide, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-­hydroxy-N-isopropylpropanamide, 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-N-cyclohexyl-N-hydroxy­propanamide, and 3-[5-(4-chlorophenyl)-1-(4-methoxy­phenyl)-3-pyrazolyl]-N-ethyl-N-hydroxypropanamide.
8. A compound of claim 1 selected from the group consisting of 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy-N-phenyl­propanamide, 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl]propylamine, 3-[5-(4-chlorophenyl)-1-­(4-methoxyphenyl)-3-pyrazolyl]propanal, 5-(4-chlorophenyl)-3-(3-oximino-propyl)-1-(4-methoxyphenyl)­pyrazole and 3-(3-hydroxypropyl)-1-(4-methyoxyphenyl)-­5-(4-tolyl)pyrazole.
9. A compound of claim 1 which is any one of the following individual compounds:
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-­N-hydroxy-N-methylpropanamide;
5-(4-chlorophenyl)-3-(3-hydroxypropyl)-1-(4-methoxyphenyl) pyrazole;
5-(4-trifluoromethylphenyl)-3-(3-hydroxypropyl)-1-­(4-methoxyphenyl) pyrazole;
1-(4-bromophenyl)-5-(4-chlorophenyl)-3-(3-hydroxypropyl) pyrazole;
sodium 8-[5-(4-chlorophenyl)-1-(4-methoxyphenyl-3-] pyrazolyl 5(Z)-octenoate.

sodium 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-­pyrazolyl propanoate;
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] -N-tert-butyl-N-hydroxypropanamide;
N-carboxymethyl-3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl) -3-pyrazolyl] -propanamide;3-[1-(4-methoxyphenyl)-5-­(4-methylphenyl)-3-pyrazolyl] -N-hydroxy-N-methyl propanamide;
3-[1-(4-methoxyphenyl)-5-(4-methylphenyl)-3-pyrazolyl] -N-methyl-N-succinyloxypropanamide;
3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] -Nʹ-Nʹ-dimethylglycinyloxy-N-methylpropanamide;
N-[3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl] propyl] -N,Nʹ-dihydroxyoxamide; or
N-acetyl-N-acetoxy [5-(4-chlorophenyl)-1-(4-methoxyphenyl) -3-pyrazolyl] propanamide.
10. A pharmaceutical composition for topical, oral, parenteral or aerosol administration, comprising an effective amount of a substituted pyrazole compound according to any one of claims 1 to 9 as active ingredient dispersed in a pharmaceutically acceptable carrier.
11. The pharmaceutical composition according to claim10 wherein said substituted pyrazole compound is capable of inhibiting both the cyclooxygenase and lipoxygenase pathways in the amount present in the composition when said composition is introduced into a mammal.
12. A substituted pyrazole compound as defined in any one of claims 1 to 9 without the provisos or a pharmaceutical composition according to claim 10 or claim 11 for use in alleviating inflammation or treating inflammatory conditions of skin, including psoriasis or other dermatitis, myocardial insufficiencies, including angina, vasospasm and infarction, asthma or allergic hypersensitivity diseases.
13. A method for synthesizing a 1,5-diaryl­-3-(omega-substituted lower alkyl)-pyrazole of any one of claims 1 to 9 comprising reacting an arylhydrazine with a 1-aryl-(omega-substitued)-alkyl-1,3-dione containing at least 4 carbons in the alkyl chain, said reaction being carried out in a solvent that is substantially inert to said reaction conditions, and said omega-substituent being substantially inert to said reaction conditions, wherein said aryl groups are the same or different and are mono- ­or di-subsubstituted phenyl wherein said phenyl substituents are selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyl, halo, hydroxy, lower alkylsulfonyl, lower alkylthio, nitro, trifluoromethyl, omega-trifluoromethyl lower alkoxy, napthyl and substituted naphthyl.
A compound having a structure that corresponds to the formula:
Figure imgb0039
    wherein R₁ and R₃ are selected from the group consisting of halo, trifluoromethyl, methyl and methoxy.
15. A compound having a structure that corresponds to the formula:
Figure imgb0040
    wherein R₁ and R₃ are selected from the group consisting of halo, trifluoromethyl, methyl, phenyl and methoxy; and
    X is selected from the group consisting of carboxy, C(O)-R₅ wherein R₅ is selected from the group consisting of N(CH₃)OH, N(t-C₄H₉)OH, NHOH, ONH(CH₃) and ONH(t-C₄H₉).
EP87304720A 1986-05-29 1987-05-28 Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same Expired - Lifetime EP0248594B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87304720T ATE97660T1 (en) 1986-05-29 1987-05-28 PHARMACOLOGICALLY ACTIVE 3-SUBSTITUTE 1,5DIARYL-PYRAZOLES AND PROCESS FOR THEIR PRODUCTION.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86799686A 1986-05-29 1986-05-29
US867996 1986-05-29
US07/042,661 US4826868A (en) 1986-05-29 1987-04-29 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US42661 1997-04-04

Publications (3)

Publication Number Publication Date
EP0248594A2 true EP0248594A2 (en) 1987-12-09
EP0248594A3 EP0248594A3 (en) 1988-11-17
EP0248594B1 EP0248594B1 (en) 1993-11-24

Family

ID=26719497

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87304720A Expired - Lifetime EP0248594B1 (en) 1986-05-29 1987-05-28 Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same

Country Status (21)

Country Link
US (1) US4826868A (en)
EP (1) EP0248594B1 (en)
JP (1) JP2512751B2 (en)
KR (1) KR960007163B1 (en)
CN (1) CN1028227C (en)
AU (1) AU596844B2 (en)
CA (1) CA1337122C (en)
DE (2) DE3788244T2 (en)
DK (1) DK170202B1 (en)
ES (1) ES2059377T3 (en)
FI (1) FI94340C (en)
HK (1) HK14094A (en)
HU (1) HU221300B1 (en)
IE (1) IE63856B1 (en)
IL (1) IL82671A0 (en)
LU (1) LU90829I2 (en)
NL (1) NL300057I2 (en)
NO (2) NO172236C (en)
NZ (1) NZ220353A (en)
PH (1) PH25126A (en)
PT (1) PT84964B (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293220A2 (en) * 1987-05-29 1988-11-30 Ortho Pharmaceutical Corporation Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing
EP0293221A2 (en) * 1987-05-29 1988-11-30 Ortho Pharmaceutical Corporation Regioselective Synthesis of 1,5-Disubstituted Pyrazoles
EP0320628A1 (en) * 1987-11-13 1989-06-21 Abbott Laboratories Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
EP0417449A1 (en) * 1989-07-31 1991-03-20 Bristol-Myers Squibb Company Arylpyrazole derivatives as platelet aggregation inhibitors
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
EP0480690A1 (en) * 1990-10-10 1992-04-15 Ciba-Geigy Ag Aqueous ophthalmic microemulsions of tepoxalin
EP0554829A2 (en) * 1992-02-05 1993-08-11 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity
FR2692575A1 (en) * 1992-06-23 1993-12-24 Sanofi Elf Novel pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
WO1995013262A1 (en) * 1993-11-12 1995-05-18 Rhone-Poulenc Rorer Limited Substituted phenyl compounds
WO1996009292A1 (en) * 1993-08-30 1996-03-28 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-(n-hydroxycarbamoyloxyalkyl)pyrazoles
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5607958A (en) * 1990-08-20 1997-03-04 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
WO1999054314A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2004037793A1 (en) * 2002-10-24 2004-05-06 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
WO2011147910A1 (en) * 2010-05-27 2011-12-01 Laboratorios Del Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
WO2011161645A1 (en) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
EP2861562A4 (en) * 2012-06-14 2015-12-16 Mayo Foundation Pyrazole derivatives as inhibitors of stat3
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898952A (en) * 1987-05-29 1990-02-06 Ortho Pharmaceutical Corporation Regioselective synthesis of a 1,5-disubstituted pyrazole
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US4956379A (en) * 1990-02-13 1990-09-11 Bristol-Myers Squibb Company Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5117054A (en) * 1991-09-26 1992-05-26 Ortho Pharmaceutical Corporation N-hydroxy, N-methyl propanamides
US5260458A (en) * 1991-09-26 1993-11-09 Ortho Pharmaceutical Corporation 2-oxo tetrahydrofuran compounds
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
GB9312853D0 (en) * 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
WO1996018399A1 (en) * 1994-12-13 1996-06-20 Euro-Celtique, S.A. Aryl thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
AU4527996A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
PT1144382E (en) 1999-08-03 2005-02-28 Ortho Mcneil Pharm Inc PROCESS FOR THE PREPARATION OF 1,5-DIARYYL-3- (SUBSTITUTED) PYRAZOLES
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
UA79804C2 (en) * 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
WO2004016741A2 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
JP4419078B2 (en) * 2002-12-02 2010-02-24 アステラス製薬株式会社 Pyrazole derivative
CN100387594C (en) * 2003-04-03 2008-05-14 麦克公司 Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
KR20060030506A (en) * 2003-07-02 2006-04-10 얀센 파마슈티카 엔.브이. Cck-1 receptor modulators
US20050020565A1 (en) * 2003-07-02 2005-01-27 Jones Todd K. CCK-1 receptor modulators
AR045536A1 (en) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd INHIBITORS OF PHOSPHODIESTERASE TYPE -IV
US20070060629A1 (en) * 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2005063716A1 (en) * 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
NZ551563A (en) * 2004-06-30 2009-06-26 Janssen Pharmaceutica Nv Alpha,beta-unsaturated esters and acids by stereoselective dehydration
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (en) * 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors.
WO2009051772A1 (en) * 2007-10-17 2009-04-23 Duke University Geranylgeranyl transferase inhibitors and methods of making and using the same
WO2012006068A2 (en) * 2010-06-28 2012-01-12 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
US8492424B2 (en) * 2010-07-01 2013-07-23 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1946370A1 (en) * 1969-09-12 1971-04-22 Byk Gulden Lomberg Chem Fab Pyrazole derivatives and processes for their preparation
DE2633992A1 (en) * 1975-08-08 1978-02-09 Schering Ag Antiinflammatory (1,4)-diphenyl-(3)-alkyl-carboxy-pyrazole - prepd. by treating corresp. (3)-halide with a cyanide, and opt. hydrolysing or reducing
EP0014847A1 (en) * 1979-02-19 1980-09-03 MERCK PATENT GmbH Pyrazole derivatives, pharmaceutical preparations containing them and process for their production
EP0086450A2 (en) * 1982-02-13 1983-08-24 Hoechst Aktiengesellschaft Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1373212A (en) * 1970-12-07 1974-11-06 Wyeth John & Brother Ltd Pyrazole compounds
US3974176A (en) * 1973-08-16 1976-08-10 Byk-Gulden Lomberg Chemische Fabrik Gmbh Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1946370A1 (en) * 1969-09-12 1971-04-22 Byk Gulden Lomberg Chem Fab Pyrazole derivatives and processes for their preparation
DE2633992A1 (en) * 1975-08-08 1978-02-09 Schering Ag Antiinflammatory (1,4)-diphenyl-(3)-alkyl-carboxy-pyrazole - prepd. by treating corresp. (3)-halide with a cyanide, and opt. hydrolysing or reducing
EP0014847A1 (en) * 1979-02-19 1980-09-03 MERCK PATENT GmbH Pyrazole derivatives, pharmaceutical preparations containing them and process for their production
EP0086450A2 (en) * 1982-02-13 1983-08-24 Hoechst Aktiengesellschaft Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTELFORSCHUNG, vol. 24, no. 4, 1974, pages 494-499; U. JAHN et al.: "Wirkungsvergleich saurer Antiphlogistika im Bradykinin-, UV-Erythem- und Rattenpfotenödem-Test" *
INDIAN JOURNAL OF CHEMISTRY, vol. 17B, May 1979, pages 472-477; V. VIRMANI et al.: "Chemistry of lactam acetals: Part II - Synthesis of pyrazoles & isoxazoles" *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293220A3 (en) * 1987-05-29 1990-07-11 Ortho Pharmaceutical Corporation Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing
EP0293221A2 (en) * 1987-05-29 1988-11-30 Ortho Pharmaceutical Corporation Regioselective Synthesis of 1,5-Disubstituted Pyrazoles
EP0293220A2 (en) * 1987-05-29 1988-11-30 Ortho Pharmaceutical Corporation Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing
EP0293221A3 (en) * 1987-05-29 1990-07-04 Ortho Pharmaceutical Corporation Regioselective synthesis of 1,5-disubstituted pyrazoles
EP0388429A4 (en) * 1987-11-13 1991-08-21 Abbott Laboratories Furan and pyrrole containing lipoxygenase inhibiting compounds
US5112848A (en) * 1987-11-13 1992-05-12 Abbott Laboratories Furan and pyrrole containing lipoxygenase inhibiting compounds
EP0388429A1 (en) * 1987-11-13 1990-09-26 Abbott Laboratories Furan and pyrrole containing lipoxygenase inhibiting compounds
EP0320628A1 (en) * 1987-11-13 1989-06-21 Abbott Laboratories Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
US4960787A (en) * 1989-02-06 1990-10-02 Ciba-Geigy Corporation Certain pyrrolyl-substituted hydroxamic acid derivatives
EP0417449A1 (en) * 1989-07-31 1991-03-20 Bristol-Myers Squibb Company Arylpyrazole derivatives as platelet aggregation inhibitors
US5607958A (en) * 1990-08-20 1997-03-04 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
US5744491A (en) * 1990-08-20 1998-04-28 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
US5744493A (en) * 1990-08-20 1998-04-28 Sanofi 3-amidopyrazole derivatives and pharmaceutical compositions containing them
US5635526A (en) * 1990-08-20 1997-06-03 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
US5616592A (en) * 1990-08-20 1997-04-01 Sanofi 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them
EP0480690A1 (en) * 1990-10-10 1992-04-15 Ciba-Geigy Ag Aqueous ophthalmic microemulsions of tepoxalin
EP0554829A2 (en) * 1992-02-05 1993-08-11 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity
EP0554829A3 (en) * 1992-02-05 1994-06-08 Fujisawa Pharmaceutical Co Pyrazole derivatives with antiinflammatory, analgesic and antithrombolic activity
US5624941A (en) * 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
EP0576357A1 (en) * 1992-06-23 1993-12-29 Sanofi Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
FR2692575A1 (en) * 1992-06-23 1993-12-24 Sanofi Elf Novel pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
WO1996009292A1 (en) * 1993-08-30 1996-03-28 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-(n-hydroxycarbamoyloxyalkyl)pyrazoles
WO1995013262A1 (en) * 1993-11-12 1995-05-18 Rhone-Poulenc Rorer Limited Substituted phenyl compounds
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6696477B2 (en) 1995-06-02 2004-02-24 Pharmacia Corporation Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO1999054314A1 (en) * 1998-04-17 1999-10-28 Boehringer Ingelheim Pharma Kg Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments
WO2004037793A1 (en) * 2002-10-24 2004-05-06 Wakamoto Pharmaceutical Co., Ltd. Pyrazole-4-alkanoate derivatives inhibiting cyclooxygenase and 5-lipoxygenase
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
WO2011147910A1 (en) * 2010-05-27 2011-12-01 Laboratorios Del Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
US9181195B2 (en) 2010-05-27 2015-11-10 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
RU2582338C2 (en) * 2010-05-27 2016-04-27 Лабораторьос Дель Др. Эстеве, С.А. Pyrazole compounds as sigma receptor inhibitors
AU2011257208B2 (en) * 2010-05-27 2016-05-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
WO2011161645A1 (en) * 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
EP2861562A4 (en) * 2012-06-14 2015-12-16 Mayo Foundation Pyrazole derivatives as inhibitors of stat3
US10138208B2 (en) 2012-06-14 2018-11-27 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations

Also Published As

Publication number Publication date
NL300057I1 (en) 2001-12-01
NO172236B (en) 1993-03-15
HU221300B1 (en) 2002-09-28
PT84964A (en) 1987-06-01
DE3788244D1 (en) 1994-01-05
FI872379A (en) 1987-11-30
DK273587A (en) 1987-11-30
CN1028227C (en) 1995-04-19
NZ220353A (en) 1989-05-29
FI94340C (en) 1995-08-25
IE63856B1 (en) 1995-06-14
EP0248594B1 (en) 1993-11-24
HUT68247A (en) 1995-06-28
JPS6322080A (en) 1988-01-29
NO2001016I1 (en) 2001-10-01
DE10199049I1 (en) 2002-01-10
ES2059377T3 (en) 1994-11-16
IE871403L (en) 1987-11-29
HK14094A (en) 1994-03-04
PH25126A (en) 1991-02-19
FI94340B (en) 1995-05-15
DE3788244T2 (en) 1994-04-14
NO872228L (en) 1987-11-30
AU7360887A (en) 1987-12-10
IL82671A0 (en) 1987-11-30
PT84964B (en) 1990-02-08
US4826868A (en) 1989-05-02
CN87103953A (en) 1987-12-09
DK273587D0 (en) 1987-05-27
DE10199049I2 (en) 2003-01-09
NL300057I2 (en) 2002-01-02
DK170202B1 (en) 1995-06-12
NO172236C (en) 1993-06-23
JP2512751B2 (en) 1996-07-03
LU90829I2 (en) 2001-11-12
KR960007163B1 (en) 1996-05-29
FI872379A0 (en) 1987-05-28
NO872228D0 (en) 1987-05-27
KR870011100A (en) 1987-12-21
EP0248594A3 (en) 1988-11-17
AU596844B2 (en) 1990-05-17
CA1337122C (en) 1995-09-26

Similar Documents

Publication Publication Date Title
EP0248594B1 (en) Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same
US5164381A (en) Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5051518A (en) Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
EP0293220B1 (en) Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing
US6083969A (en) 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
US4743587A (en) Hydroxamic acid based collagenase inhibitors
FI71929C (en) FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ETERFOERENINGAR SAMT VID DERAS FRAMSTAELLNING ANVAENDBARA MELLANPRODUKTER.
US4861798A (en) Lipoxygenase inhibitory compounds
US5242940A (en) Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
US5110831A (en) Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
EP0538416B1 (en) Substituted monocyclic aryl compounds exhibiting selective leukotriene b 4 antagonist activity
US4731382A (en) Lipoxygenase inhibitory phenylalkanohydroxamic acids
US4742058A (en) Polyprenyl compound, process for the production thereof and drug containing the same
AU630261B2 (en) Novel 2-substituted 4-(3-alkyl-5-tert.-butyl-4-hydroxyphenyl)thiazoles, processes for their preparation, pharmaceuticals containing them and their use
HU203722B (en) Process for producing substituted hydroxyamines and pharmaceutical compositions containing them
US4898952A (en) Regioselective synthesis of a 1,5-disubstituted pyrazole
US4230719A (en) Novel 2-[4-(3-methyl-2-thienyl)phenyl]propionic acid and pharmaceutically acceptable salt thereof and method for treating symptoms of inflammation and pain
WO1986007357A3 (en) Cyclopentapyrazole and tetrahydroindazole compounds
US4782085A (en) Arylhydroxamates and use thereof in treating allergies
GB2132618A (en) Dibenzocycloheptenylidenes
JP2518497B2 (en) Antilipemic agent
EP0293221A2 (en) Regioselective Synthesis of 1,5-Disubstituted Pyrazoles
EP0087858A1 (en) New chromanone compounds and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19890419

17Q First examination report despatched

Effective date: 19901113

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 97660

Country of ref document: AT

Date of ref document: 19931215

Kind code of ref document: T

ITF It: translation for a ep patent filed
REF Corresponds to:

Ref document number: 3788244

Country of ref document: DE

Date of ref document: 19940105

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3009905

ET Fr: translation filed
REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 97660

Country of ref document: AT

Kind code of ref document: T

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

EPTA Lu: last paid annual fee
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2059377

Country of ref document: ES

Kind code of ref document: T3

26N No opposition filed
EAL Se: european patent in force in sweden

Ref document number: 87304720.3

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: TEPOXALIN; REGISTRATION NO/DATE: EU/2/00/028/001 20010313

Spc suppl protection certif: 01C0034

Filing date: 20010911

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: 0190030-7, 20010313

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: GBCTFFSPC/GB2001/038, 20010907

REG Reference to a national code

Ref country code: FR

Ref legal event code: CR

Free format text: FRCR 2001C0034, 20010911

REG Reference to a national code

Ref country code: LU

Ref legal event code: CCP

Free format text: LUCCP 90829, EXPIRES: 20120528

REG Reference to a national code

Ref country code: AT

Ref legal event code: ESZA

Free format text: PRODUCT NAME: TEPOXALIN UND DESSEN PHARMAZEUTISCH VERTR?GLICHE SALZE

Spc suppl protection certif: SZ 23/2001

Filing date: 20010910

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

REG Reference to a national code

Ref country code: NL

Ref legal event code: AC1

Free format text: NLAC1 300057, 20010910

REG Reference to a national code

Ref country code: AT

Ref legal event code: EEZF

Spc suppl protection certif: SZ 23/2001

Filing date: 20010910

Extension date: 20120528

Effective date: 20011105

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: NL

Ref legal event code: KC1

Free format text: NLKC1 300057, 20070528, EXPIRES: 20120527

CCPV Be: grant of a complementary protection certificate

Free format text: 2001C/034, EXPIRES: 20120528

REG Reference to a national code

Ref country code: FR

Ref legal event code: CY

Free format text: FRCY 01C0034, 20010911, EXPIRES: 20120527

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: GBCTFGSPC/GB01/038: 20020516, EXPIRES: 20120527

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0190030-7

Spc suppl protection certif: 0190030-7

Ref country code: SE

Ref legal event code: SPCG

Free format text: 0190030-7, 20010313

Spc suppl protection certif: 0190030-7

Filing date: 20010313

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20060413

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20060503

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20060505

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20060511

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060515

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060524

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060525

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20060530

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060531

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20060601

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20060621

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060712

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070528

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Ref country code: GB

Ref legal event code: CTFE

Free format text: SPC/GB01/038: 20070528, EXPIRES: 20120527

Spc suppl protection certif: SPC/GB01/038

Filing date: 20070528

Expiry date: 20120527

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20070528

REG Reference to a national code

Ref country code: AT

Ref legal event code: EELA

Ref document number: 97660

Country of ref document: AT

Kind code of ref document: T

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070527

BE20 Be: patent expired

Owner name: *ORTHO PHARMACEUTICAL CORP.

Effective date: 20070528

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120509

REG Reference to a national code

Ref country code: BE

Ref legal event code: CCRE

Owner name: *ORTHO PHARMACEUTICAL CORP.

Free format text: PRODUCT NAME: TEPOXALIN; REGISTRATION NO/DATE: EU/2/00/028/001 20010313

Spc suppl protection certif: 2001C/034

Filing date: 20010911

Expiry date: 20070528

Extension date: 20120528

Effective date: 20120528

REG Reference to a national code

Ref country code: GB

Ref legal event code: SPCE

Free format text: PRODUCT NAME: TEPOXALIN; REGISTERED: UK EU/2/00/028/001 20010313; UK EU/2/00/028/002 20010313; UK EU/2/00/028/003 20010313; UK EU/2/00/028/004 20010313; UK EU/2/00/028/005 20010313; UK EU/2/00/028/006 20010313; UK EU/2/00/028/007 20010313; UK EU/2/00/028/008 20010313

Spc suppl protection certif: SPC/GB01/038

Filing date: 20010907

Expiry date: 20070528

Extension date: 20120527

Ref country code: NL

Ref legal event code: SPCX

Free format text: PRODUCT NAME: TEPOXALINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/2/00/028/001 - EU/2/00/028/008 20010313

Spc suppl protection certif: C300057

Filing date: 20010910

Expiry date: 20070528

Extension date: 20120527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070529

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCX

Ref document number: 97660

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: TEPOXALIN UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE; REGISTRATION NO/DATE: EU/2/00/028/001- EU/2/00/028/008 20010313

Spc suppl protection certif: 23/2001

Filing date: 20010910

Expiry date: 20070528

Extension date: 20120528

Effective date: 20120528